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ABSTRACT OF THESIS 
 
 
 
CHONDRODYSPLASIA-LIKE DWARFISM IN THE MINIATURE HORSE 
 
Dwarfism is considered one of the most recognized congenital defects of animals 
and humans and can be hereditary or sporadic in cause and expression.  There are two 
general morphologic categories within this vastly diverse disease.  These categories are 
disproportionate and proportionate dwarfism and within each of these there are numerous 
phenotypes which have been extensively described in humans, and to a lesser extent in 
dogs, cattle, mice, chickens, and other domestic species.  Ponies and Miniature horses 
largely differ from full size horses only by their stature.  Ponies are often defined as those 
whose height is not greater than 14.2 hands; however the maximum height for Miniature 
horses is constitutionally defined as 8.2 hands.  Dwarfism is not considered a desirable 
genetic trait for Miniature horses.  A majority of these conformationally inferior horses 
showed consistent physical abnormalities typical of disproportionate dwarfisms as seen in 
other mammal species.  A whole genome scan with the Illumina Equine SNP50 chip 
clearly implicated a region on ECA1 as being associated with dwarfism of horses. The 
region implicated on the horse chromosome 1 (Equus Caballus; ECA1) contained a 
candidate gene for dwarfism, aggrecan (ACAN).  Mutations were found in Exons 2, 6, 11 
and 15 with each mutation associated with a distinct type of dwarfism.  These mutations 
are independently transmitted throughout the population.  Absence of normal 
homozygotes for these mutations and absence of normal horses which were heterozygous 
for these mutations indicated that these alleles caused dwarfism in those genotypes.  
These genotypes did not explain all observed dwarves in this population.   
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Chapter 1 
The Miniature Horse Breed 
 
Summary 
 
The Miniature horse breed is defined by a registry for horses of small stature. 
Miniature horses are a breed of horse in which the only defining characteristic is a 
maximum height up to 34 inches (AMHA, American Miniature Horse Association 2013) 
or up to 38 inches (AMHR, American Miniature Horse Registry 2013) at the base of the 
mane, depending on the registry.  Any color combination and any physical type of 
Miniature is acceptable to be registered as long as the height requirement is met.  This 
type of flexibility in the breed’s characteristics requirements has allowed the Miniature 
horse industry to explode in popularity all over the world.   
 
Until very recently, open studbooks for Miniature registries allowed the use of 
other pony breed crosses into the gene pool of the Miniature breed as long as the resulting 
offspring was under the height restriction when mature.  Enthusiasts of all backgrounds 
and fanciers have been allowed to breed the colors and body types they have so desired 
without the registries’ constraints that would be typical for pure-bred horse registries. 
Worldwide, there are dozens of Miniature horse registries. Some organizations stress 
breeding of Miniatures with proportional large horse characteristics, others promote the 
Miniatures to retain traditional pony characteristics (AMHA 2013; AMHR 2013; BMHS, 
British Miniature Horse Society 2013). 
 
The two largest registries in the United States (as well as the world) for Miniature 
Horses are; the American Miniature Horse Association (AMHA) and the American 
Miniature Horse Registry (AMHR).  The AMHA standard of perfection of today suggests 
that if a person were to see a photograph of a Miniature horse, without any size reference, 
it would be identical in characteristics, conformation, and proportion to a full-size horse.   
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General appearance is to be of a well-balanced horse with correct conformation 
characteristics required of most large horse breeds with any color or marking pattern, as 
well as any eye color.  The head should be in proportion to length of neck and body yet 
broad and relatively short from eye to muzzle with large eyes set wide apart with medium 
sized ears carried alertly.  The neck is to be flexible and lengthy blending smoothly into 
the withers with a clean well-defined throat latch allowing flexibility at the poll.  
Shoulders are to be well angulated and long-sloping that allows a free moving stride with 
alert head carriage.  The body is to be well muscled and balanced with a short back and 
proportionate with ample bone.  The topline should be smooth and level with a trim 
barrel, deep girth and flank with hindquarters that are long with a well-muscled hip, thigh 
and gaskin. The croup should be the same height as the withers and tail set smoothly 
rounding at the rump.  The legs should provide ample ability for smooth fluid gates when 
in motion.  When viewed from front or back the legs are to be set straight and parallel 
with pasterns and hooves to hold a 45 degree angle blending smoothly.  Hooves should 
be round and compact and trimmed appropriately for an unshod horse (AMHA 2013).   
The standard of perfection for the AMHR Miniature is similar to the AMHA standard, 
however with a taller height limit.  For its size, the Miniature is quite possibly the 
strongest of all horse and pony breeds. It can pull twice its own weight under 
circumstances where a draft horse can only pull approximately half its own weight.  
Miniatures are found worldwide including North America, Europe, Asia, Africa, South 
America and Australia, though the majority of the breed population is in Europe and 
North America.   
 
Introduction 
 
History and Foundation of the Miniature Horse 
The foundation of the Miniature horse breed originated from a large number of 
different populations worldwide.  Many different pony breeds (originally landraces) have 
been bred for small size, including the Shetland pony, Exmoor pony, and Dartmoor pony.  
The Exmoor and Dartmoor have height variations from 12.3 hands down to 44 inches and 
the Shetland down to 28 inches; however, there is no minimum height for these registries 
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(Dartmoor Pony Society 2013; Exmoor Pony Society 2013; Shetland Pony Stud-Book 
Society 2013).  The Miniature is the smallest equine breed known to exist with no 
minimum height (AMHA 2013; AMHR 2013). 
 
In 17th century Europe, according to records of 1650 from the court of the French 
King Louis XIV (1643-1715), third monarch of the Bourbon family, the presence of tiny 
horses among the exotic animals in the king’s zoo are noted.  Paintings and articles 
featured minute horses by 1765 (International Museum of the Horse, Kentucky Horse 
Park 2013).  However, many early Miniature sized horses were not pets of kings and 
queens. Many were used to work in the English Midlands, Wales and Northern European 
coal mines as pit ponies until the European industrial revolution (International Museum 
of the Horse, Kentucky Horse Park 2013).  Later in other countries such as the United 
States, these pit ponies were used until the industrial revolution (Naviaux 1999).   
 
In other parts of the world, the Miniature horse has had similar foundations to 
those in Europe and North America.  The Falabella Miniature horse was originally 
developed in Argentina in 1868 by Patrick Newell.  When Mr. Newell died, the herd and 
breeding methods were given to Newell's son-in-law, Juan Falabella.  Juan supposedly 
added additional bloodlines including the Welsh Pony, Shetland pony, and small 
Thoroughbreds; however, that could not be verified.  Utilizing extensive inbreeding, he 
was able to produce small size within the herd (Naviaux 1999).  South Africa's Miniature 
horses were developed in that nation and are recognized as the South African Miniature 
horse.  Mr. Wynand de Wet of Lindley, South Africa, started in 1945 with two Shetland 
pony mares and a Shetland stallion. Through strict selection, the offspring became 
smaller and in 1991 Mr. de Wet apparently produced a mare that was only 25 inches tall 
(66cm) (South African Miniature Horse Breeders Society 2012).     
 
The foundation horses of the European Miniature registries exhibited physical 
characteristics with striking similarities to the European pony breeds listed earlier, 
including coat color patterns.  The Shetland pony breed, originating from the Shetland 
Isles, was a significant contributor to the foundation of the European Miniature horse.  In 
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appearance, European Shetlands and Foundation and Classic American Shetlands have 
very similar characteristics to Miniatures which include a small head, sometimes with a 
dished face, wide spaced eyes and small and alert ears (AMHA 2013; AMHR 2013; 
ASPC, American Shetland Pony Club 2013).  The original United Kingdom Shetland 
Pony breed, as well as the founding European Miniature horses, had a short, muscular 
neck, compact, stocky bodies, and short, strong legs and a shorter than normal cannon 
bone in relation to their size.  A short broad back and deep girth are universal 
characteristics as is a springy stride.  UK Shetland ponies have long thick manes and tails 
and a dense double winter coat to withstand harsh weather.  These are identical 
characteristics to the European Miniature and the early American Miniature horse 
(Naviaux 1999).  In general, modern European Miniatures tend to preserve more of the 
original characteristics of the breed and are often stockier than their current American 
Miniature horse relatives (AMHA 2013; AMHR 2013; BMHS 2013). 
 
This earliest history of the Miniature horse in the United States is similar to that 
of the European Miniature.  The first Shetland ponies in the United States, for which 
there are written records, were imported in 1885 by Eli Elliot.  These ponies provided the 
foundation stock for the development of the American Shetland registry (ASPC 2013) 
and later the development of the American Miniature Horse Registry (AMHR) (Naviaux 
1999).  Some of these Shetlands were crossed with ponies of other breeds, including the 
Hackney pony, Welsh pony, POA (Pony of America), and Harness Show Pony.  The 
breeding of American Shetlands was mainly centered in Indiana, Illinois and Iowa.  The 
Pony of the Americas breed (POA) has its origin in America, where Leslie Boomhower, 
an Iowa breeder of Shetland Ponies, founded the breed in 1954.  He acquired an 
Arabian/Appaloosa mare that had been accidentally bred to a Shetland pony stallion. 
Boomhower named the resulting colt Black Hand, and he became the foundation sire for 
the POA breed.  POA breeding was centered in Indiana, Illinois and Iowa like the 
Shetlands (Dutson 2005).  This region has been universally recognized as having some of 
the founding Miniature horse lines.  Most importantly some of those founding Miniature 
horse breeders were well-known Shetland breeders.  This coincidence leads to a vast 
amount of anecdotal evidence of an infusion of bloodlines from certain large pony breeds 
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such as the Welsh, American Shetland, and POA, as some of the founding lines of the 
Miniature horse (ASPC 2013; AMHR 2013). Some American Shetland pony breeders in 
Virginia started to gather the smallest ponies they could find beginning in the 1930’s 
through the 1960’s to breed a “midget pony”.  Some of these were to be among the first 
Miniature horses registered in the AMHR studbook in 1972 (Naviuax 1999).   In the 
United States, the Miniature horse breed was refined conformationally even more during 
the later 20th and early 21st century by utilizing more lines from sources that include the 
Modern Shetland and Hackney Pony (AMHR 2013). 
 
Miniatures, like the Shetland pony, appear with most colors and color patterns 
including black, chestnut, bay, brown, gray, palomino, dun, roan, cremello, silver dapple 
pinto, overo, sabino and tovero.  Interestingly, the Miniature breed also has appaloosa 
and champagne colors.  Registered European Shetland ponies are not Appaloosa, nor do 
they carry the champagne gene.  American Shetland ponies do carry appaloosa and 
champagne.  Evaluating the history of some of these other pony breeds mentioned above, 
modern DNA testing for coat color, and breed registry constrictions of color within each 
breed, brings about an interesting question.  When observing the existence of appaloosa 
and champagne coat colors in the Miniatures all over the world, how does a relatively 
new breed of horse with registries less than 40 years old express almost ALL colors seen 
in equines?  This observation quite possibly makes coat color testing a sound and helpful 
technique to investigate of the Miniature horse’s multiple breed history.   
 
Genetic Background and selection for size in the Miniature 
The genetic background of the Miniature horse is quite diverse, based on the 
heterogeneous origin of the foundation stock.  Genetic studies have shown extensive 
variation at the level of blood groups, biochemical polymorphisms and DNA markers 
(Bailey, personal communication).  The major premise for many breeders has been to 
produce small, well-proportioned horses.  Ponies and Miniature horses differ from full 
size horse only by their stature. Ponies are often defined as those whose height is not 
greater than 14.2 hands; however, the maximum height for Miniature horses is 
constitutionally defined as 8.2 hands. The entire premise of the Miniature horse is to 
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breed the smallest most correct and proportionate horse in Miniature. This reduced 
stature is usually the cumulative effect of hundreds of genes, each having a small impact 
on stature. Unfortunately, there are also dwarfism genes which greatly reduce statute and 
may negatively impact health and reproduction. This is not considered a desirable genetic 
trait for Miniature horses.  Some breeders focused on selection for extreme diminutive 
size in the mid to latter part of the 20th century at a time when the breed was also 
experiencing great popularity and rapid population growth.  Consequently, any gene 
which decreased size was selected without regard to its effect on conformation or fitness.  
While reduced stature can be attained though many generations of breeding for genes 
which combine to reduce size, other genes can reduce stature rapidly (in a single 
generation) and produce phenotypes which are commonly referred to as dwarfs.   
 
Genetics of Stature 
Stature in all organisms is the additive interaction of dozens if not hundreds of 
genes within an individual that determines its ultimate mature height.  This polygenic 
trait is primarily due to genetics (80 – 90 %) and only slightly affected by other 
environmental factors. This mature height has been shown to be quite variable within 
certain isolated breeding populations of animal species including humans.  Genome-wide 
association studies (GWAS) using SNP (Single Nucleotide Polymorphism) analyses have 
implicated numerous chromosomal sites involving genes that regulate to some degree 
mature height in humans (Allen et al. 2010). 
 
Gudbjartsson et al. (2008) discovered that candidate genes in those chromosomal 
sites that were known to be involved in growth could be divided into three functional 
groups.  The groups were based on skeletal development, processes involving mitosis and 
chromosomal segregation, and cartilage composition.  A total of 58 loci were found to be 
significantly associated within Caucasians.  It was estimated that individually, each of the 
candidate genes found in those regions only had a minute effect, (0.4 cm) on mature 
height.  However, collectively these same genes may wield a significant effect and 
account for roughly 4% of mature stature.  The more “tall” alleles an individual may 
have, the taller the individual ultimately becomes.  Weedon et al. (2008) discovered a 
7 
 
five cm difference in adult stature between individuals with 17 or fewer “tall” alleles 
when compared to those individuals with 27 or more.  A study of Koreans by Kim et al. 
(2010) found another 15 loci associated with stature.  With nearly 200 linked loci 
identified to stature suggesting almost 700 genes identified having some involvement 
with height determination in humans, this scenario can only explain approximately 16% 
of its variation (Allen et al. 2010). 
 
 Stature variation within various animal species has been shown to exist to some 
degree.  Domesticated animals have been shown to have great variation in height within a 
species (Clutton-Block 1999). GWAS studies in cattle, horses and dogs utilizing genetic 
information gleamed from GWAS stature studies in humans have strongly suggested that 
polymorphic regions affecting human stature also affect stature in these domesticated 
species.  Pryce et al. (2011) looked at orthologous genes that could be mapped to Bovine 
Genome v4.0.  Fifty-five genes were found and mapped with 879 SNPs in the Bovine 
Build that were known to be associated with stature in humans.  Dairy and beef cattle 
populations were tested.  It was found that 10 of the genes associated in humans were 
associated with stature in dairy cattle and 12 with stature in beef cattle.  Two of the 
associated genes for stature in humans were also found to be among the genes in this 
study; HMGA2 within the Beef cattle and LCORL in the Dairy cattle. 
 
Makvandi-Nejad et al. (2012) reported four loci on four different chromosomes 
associated with determining 83% of height across 16 horse breeds ranging from the 
smallest known breed (Miniature) to the largest (Shire).  Of the genes linked to the 
GWAS scan SNPs, the highest valued genome-wide associated SNP was on chromosome 
3 located 100 kb upstream of the ligand dependent nuclear receptor corepressor-like 
(LCORL) gene.  It is a transcription factor that has repeatedly been associated with 
human height (Allen et al. 2010; Gudbjartsson et al. 2008; Weedon et al. 2008; Kim et 
al. 2010).  The association value at this SNP was almost the maximum possible in the 16 
breed scan.  The alleles associated with this gene segregate by horse size close to perfect. 
LCORL and/or HMGA2 have been found to be strongly associated with stature variation, 
confirming what has been seen in humans, cattle and mice. 
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One of the most compelling finds in stature determination was done by Sutter et 
al. (2007).  Using GWAS, Sutter was able to pinpoint a single allele of IGF-1 as a major 
determining factor in dog size across 143 breeds.  This evidence showed clear evidence 
that a single gene/allele can have a significant impact on the mature stature of an 
organism, therefore altering the notion that height is strictly a quantitative trait, especially 
in certain highly inbred organisms with specific characteristics.  Considering the GWAS 
studies in cattle, dogs, and horses, it is becoming increasingly evident that a short list of 
genes repeatedly selected is responsible for stature in the domestication of animals.       
 
GWAS in stature has proven an effective tool in giving insight into controlling 
genetic forces of complex polygenic traits.  The issue of stratification is highly unlikely 
to cause the same genetic artifacts across different species.  It also gives tremendous 
strength to the physiological relationship of a gene in linkage disequilibrium to an 
associated single nucleotide polymorphism and a specific trait, as seen in dogs.  In 
consideration of GWAS and stature studies in various different human races and animal 
species, it gives strong argumentative information that there is no known mechanism 
associating genes found with GWAS and complex traits such as stature, with those genes 
that show linkage (Pryce et al. 2011). 
 
Genetics and Biology of Dwarfism 
Dwarfism is considered one of the most recognized congenital defects of animals 
and humans and can be hereditary or sporadic in cause and expression. There are two 
general morphologic categories within this vastly diverse disease. These categories are 
disproportionate and proportionate dwarfism and within each of these there are numerous 
phenotypes which have been extensively described in humans, and to a lesser extent in 
dogs, cattle, mice, chickens, and other domestic species.  Among humans, over 200 
known distinct types of dwarfism have been reported, each with a different underlying 
cause.  The approximate worldwide population of dwarfism numbers 190,000 in humans.  
Causes of dwarfisms in humans can involve genes responsible for hormone production 
and/or recognition, metabolism, cartilage development, pituitary gland hormones, thyroid 
gland hormones, and bone growth plate development. The most common type of 
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dwarfism in humans is Achondroplasia, which affects about 1 in every 40,000 children 
worldwide.  This number varies widely depending on the country. Eighty percent of all 
human dwarfisms are Achondroplasia.  This disproportionate dwarfism involves mostly 
the shortening of the limbs with an averaged sized trunk, enlarged head with a prominent 
forehead with other lesser skeletal malformations.  Achondroplasia is caused by a single 
base substitution of one of two different bases G → A or G → C, resulting in an amino 
acid change from arginine to glycine (Shiang et al. 1994).  This FGFR3 (fibroblast 
growth factor – 3) mutation is most commonly sporadic with a small portion being 
inherited.  It is estimated that 150,000 people have Achondroplasia worldwide.  The 
FGFR3 gene is part of a family of genes responsible for determining cell type, regulation 
of cell growth and division, blood vessel formation and embryo development.  Besides 
Achondroplasia, different mutations in FGFR3 can cause other more rare types of 
dwarfisms; Hypochodroplasia, SADDAN (Severe Achondroplasia with Developmental 
Delay and Acanthosis Nigricans) (Bellus et al. 1995), and Thanatophoric Dysplasia 
(Pannier et al. 2009).   
 
Turner Syndrome is a type of dwarfism caused by a female having a severely 
altered or missing X chromosome.  One of the side effects of the missing X is that she is 
unusually short in stature (4‘8” or less).  The male version of this disease is called 
Noonan Syndrome.  Males are usually short as well (50-70% of the cases).  Both males 
and females have other characteristic abnormalities with facial structure, heart defects 
and other skeletal malformations.   
 
Pituitary dwarfism (hypophysis) is the result of the anterior half of the pituitary 
gland not producing enough growth hormones involving the gene POU1F1 (formerly Pit 
1, Pituitary-specific positive transcription factor 1) (Irie et al. 1995; Hendriks-Stegeman 
et al. 2001), or no hormones at all (Panhypopituitarism).  Pituitary dwarfism causes the 
person to have proportionate body structures for their decreased height compared to age 
of development. Other abnormal characteristics may be involved specifically when 
dealing with mutations in the gene PROP-1 (Pituitary-Specific Homeodomain Factor), 
and its related CPHD (Combined Pituitary Hormone Deficiency) due to the hormone 
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cascade necessary for growth and development involving multiple hormones (Bottner et 
al. 2004).  Hypopituitarism may be acquired after childbirth from causes other than 
genetic.  It could be caused by trauma to the pituitary gland by injury or from surgery 
(tumor removal) or even environment.   
 
Cretinism is caused by a decrease in thyroid hormone production by the thyroid 
gland during childhood resulting in a type of dwarfism characterized by short stature with 
disproportionally small limbs and other skeletal structures, mental retardation and lack of 
sexual maturity.  This can be caused by environmental (endemic goitre) or genetic factors 
(congential nongoitrous hypothyroidism) caused by mutations in the Thyroid Hormone 
Receptor Alpha (THRA) gene (Bochukova et al. 2012; van Mullem et al. 2012).   
 
The vast number and variety of dwarfism in the humans as compared to all other 
species is quite interesting and complex.  One consideration to the perpetuation and 
complexity of these types of dwarfisms could be due to the increasing public acceptance 
of the diseases, modern medicine assisting in survival of individuals affected by a type of 
dwarfism and the individuals’ desire of reproduction. Other mammalian dwarfisms have 
been shown to exist.  In cattle specifically, disproportionate dwarfism has been reported 
in different breeds which include; Aberdeen, Angus, Dexter, Holstein, Hereford, 
Japanese Brown and Shorthorn.  Mutations causing dwarfism have been reported in 
Japanese Brown and Australian Dexter cattle, as well as expression data showing down 
regulation of IGF-1 in Holstein dwarfs (Takeda et al. 2002; Cavanagh et al. 2007; Blum 
et al. 2006).   Bovine Chondrodysplastic Dwarfism (BCD) in Japanese Brown cattle is an 
autosomal recessive disorder (Takeda et al. 2002).  The gene responsible for BCD is 
limbin (Lbn) and is expressed in the epiphysial growth plates of long bones (Moritomo et 
al. 1992).    In the mid thru later 20th century, the Hereford, Angus, and Shorthorn cattle 
breeds experienced a type of dwarfism.  Interestingly, during that period of time cattle 
breeders were producing cattle of a particular type and build with heavy or thick bone 
and highly muscular but small in height.  Physical characteristics used to describe the 
dwarfism in cattle were similar to human Achondroplasia.   
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Currently, only one other equine breed with recently documented dwarfism is the 
Friesian (Back et al. 2008).  GWAS scan was performed and associated a 2-MB region of 
chromosome 14 (Orr et al. 2010).  This dwarfism in Friesians has a phenotype quite 
similar to skeletal atavism in the Miniature horse (Tyson et al. 2004; Rafiti et al. 2013).  
The Friesian dwarfism has shown to be inherited as autosomal recessive, but as yet the 
genetic cause is unknown.  With recent and past GWAS done regarding dwarfism, other 
diseases and stature, this process was used as the basis for this study conducted to 
discover the genetic basis for dwarfism in Miniature horses. 
 
Aggrecan and Dwarfism 
Gleghorn et al. (2005), was first to identify a mutation in Aggrecan (ACAN) that 
caused a form of human dwarfism.  Spondyloepiphyseal Dysplasia (SED) type 
Kimberley (SEDK) is an autosomal dominant mild condition that expresses 
characteristics similar to (SED) however with severe premature arthritis. SED is a 
heterogeneous collection of disorders that are characterized by general shortening of the 
limbs and torso of individuals.  SEDK was mapped to a locus in the human genome that 
contained ACAN, and discovered a single base insertion in the exon 12 variable repeat 
region of ACAN causing a premature stop codon and thus a truncated non-functional 
protein that is ~60% of normal size.  Gleghorn proposed that the novel protein 
accumulated in the Endoplasmic Reticulum (ER) and not in the Extra-Cellular Matrix 
(ECM) as was seen in the chicken nanomelic mutation (Li et al. 1993; Vertel et al. 1993) 
and in the CMD mouse model (Watanabe et al. 1997) and thus caused a reduction in 
steady state levels of Aggrecan (ACAN) in the ECM.  These observations in animal 
models suggest that even the reduction of normal levels of functional ACAN in the ECM 
is sufficient to cause a dwarf phenotype.  Therefore, it was proposed that the SEDK 
mutation may result in lower mRNA amounts of functional ACAN thus causing the mild 
dominant heterozygous condition seen.  
 
Thompson et al. 2008, describes the condition SEMD Aggrecan Type involving a 
recessive mutation in the C-type Lectin domain of ACAN in humans.  Characteristics 
involve rhizomelia and mesomelia of the limbs with no bowing, and severe 
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brachydactyly in the hands and phalanges.  Torsos were barrel chested with mild lumbar 
lordosis and shortened necks.  Facial features included posteriorly rotated ears, 
prognathism that was slightly low set with severe midfacial hypoplasia and almost absent 
nasal cartilage and macrocephaly.  The mutation was inherited from both parents who 
were heterozygotes for the (c.6799 G → A) p. D2267N mutation (aspartic acid → 
Asparagine) and the unaffected sibling was homozygous for the WT.  An interesting side 
note from the data showed the two parents to be somewhat short (59” – 60”) but 
proportionate and the homozygote WT sibling was 70” in height. 
 
Stattin et al. 2010, describes an autosomal dominant familial dwarfism 
osteochondritis dissecans (OCD) which develops early onset osteoarthritis.  This familial 
type affects numerous joints within the individual and is accompanied with a 
disproportionate short stature.  A missense mutation was found in the G3 domain of the 
C-type lectin domain (CLD) of ACAN involving a valine to methionine.  This mutated 
residue is located within the hydrophobic core and is physically directly below the ligand 
binding surface of the CLD.  This missense mutation may alter the binding surface 
conformation.  Loss of ligand binding interaction was shown using mammalian-
expressed recombinant G3 fragments.  This loss of ECM ligand binding and interaction 
leads to the disruption of the ECM framework, ultimately leading to unstable cartilage 
causing OCD and early osteoarthritis. 
 
ACAN mutations are known to cause dwarfism in humans as well as animals.  In 
avian species the disease nanomelia (nm) is an autosomal recessive homozygous 
embryonic lethal mutation.  Embryos express a phenotype of hypoplastic limbs and a 
parrot shaped beak.  The single based substitution causes a premature stop codon to occur 
in the CS-1 region.  This makes a truncated ACAN protein that was shown neither to be 
processed post translation nor to be secreted into the ECM (Li et al. 1993).   
 
Canvanagh et al. (2007) found two different mutations in ACAN inherited in 
Dexter cattle that cause the same phenotype.  The Dexter Cow has a type of dwarfism 
inherited as autosomal co-dominant where the carriers show characteristic short legs 
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compared to non-carriers.  This condition has been well documented anecdotally since 
the 19th century.  Lethal homozygote affected calves are aborted in late gestation with 
micromelia of the limbs, cleft palate, extreme shortening of ribs and trunk with herniated 
abdomen.  The head is abnormal with midface hypoplasia and substantial prognathia with 
protruding tongue.  Two separate mutations were found in two different families.  One 
family contained an insertion in exon 11 between bp 2266_2267 of GGCA, which 
introduced a frameshift and caused a stop codon in exon 11. The frameshift occurred at 
amino acid position 756 subsequently, the stop codon is amino acid position 914.  This is 
substantially shorter than the normal ACAN protein of 2327 amino acids. The transition 
mutation in exon 1 of another family (-198C→ T) is predicted to introduce a new ATG 
start codon 199bp upstream of the normal start codon which produces a 91 amino acid 
protein bearing no resemblance to the ACAN protein due to the frameshift nature of the 
new start codon. These two variants account for all cases of Dexter chondrodysplasia 
tested and carriers.   
 
Mice have been ideal models for genetic research in mammals.  Cartilage Matrix 
Deficiency (CMD) mice were the first known genetic disorder of proteoglycans identified 
in a mammal species (Rittenhouse et al. 1978).  It is an autosomal recessive disorder 
(Kimata et al. 1981) where homozygous CMD mice are born with severe dwarfism 
characterized by short limbs, tail, and snout with a cleft palate resulting in death shortly 
after birth.  The presumed cause of death is the malformation of the tracheal cartilage.  
The mutation is a 7-bp deletion in exon 5 of ACAN causing an early termination codon in 
exon 6 (Watanabe et al. 1994).  Heterozygous cmd mice are noted to have slight 
dwarfism and develop age-related hyperlordosis in the cervical spine and kyphosis in the 
thoraco-lumbar spine resulting in spastic abnormal gait causing marked decrease of 
movement with eventual death due to inability to eat.  Expression data showed decreased 
ACAN mRNA in both heterozygotes (81% of normal) and homozygotes (41% of normal).  
Chondroitin sulfate levels were 87% of normal in the spine of heterozygotes from WT 
mice (Watanabe 1997). 
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Aggrecan Structure and Function  
 The investigation of dwarfism led us to a study of the gene for ACAN, as 
described in chapter 2.  Mutations of ACAN have been found to cause dwarfism in several 
species (Li et al. 1993; Watanabe et al. 1994; Cavanagh et al. 2007; Tompson et al. 
2009).  Therefore, reviewing the genetics and biology is pertinent to this introduction.   
 
Synovial joint structure and function are intricately designed to provide smooth 
gliding surfaces for joint movements with little wear and tear for most of the organism’s 
lifespan.  This integral design within structures of joints involves articular cartilage 
covering the joint’s areas of wear.  These areas are specifically composed of hyaline 
cartilage which is simply a thin, smooth and firm layer able to provide a cushioned 
surface to sustain weight bearing loads (Kiani et al. 2002).  The cellular composition of 
cartilage is chondrocytes and the extra-cellular matrix (ECM) they produced.  The 
biochemical makeup of cartilage and physical structure and function of joints are vitally 
reliant on the integrity of the ECM (Kiani et al. 2002). The matrix molecules in cartilage 
include type II collagen, hyaluronan (HA), proteoglycans, glycoproteins and a variety of 
elastic fibers.  Proteoglycans are made up of a family of glycoconjugates with a central 
core protein.  This core protein is then covalently bonded, in post-translational 
modification, to one or more glycosaminoglycan (GAG) side chains (Wight et al. 1992).  
A majority of all proteoglycans function as aggregates (Sajdera et al. 1969) created by 
the non-covalent bonding with hyaluronan and link protein (Hardingham et al. 1972; 
Hardingham et al. 1973; Heingard et al. 1974).   
 
When proteoglycans are in high concentration, it creates a substantial osmotic 
swelling effect drawing water into the tissues where the proteoglycans are located.  The 
most essential cartilage proteoglycan to the normal performance of articular cartilage is 
ACAN.  Up to 10% of cartilage is made up of proteoglycans, and of those, ACAN is the 
main constituent.  This is one of the large multi-modular aggregating chondroitin sulfate 
proteoglycans within the ECM (Zimmermann et al. 1989).  The molecule is essential to 
the proper function of articular cartilage by supplying a hydrated gelatinous constitution 
formed by its interaction with hyaluronan and link protein.  It is found in other connective 
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tissues in a lesser amount as well. This influx of water causes the ACAN-rich matrix to 
swell and expand.  This matrix in the water swollen state is critical to the biomechanical 
properties of cartilage and the ability to allow joints to handle wear and weight bearing 
loads.  The interaction of ACAN with collagen is another vital characteristic to the 
cartilage’s functional ability of stiffness and resistance to deforming under stress.  ACAN 
is significantly restricted within the matrix with regards to its mobility which gives it the 
ability to retain fluid or the redistribution of water (Mow et al. 1989).  Figure 1.1 shows a 
schematic of the interactions of the proteins within the human ECM. 
 
 
             Figure 1.1. Combined properties and spatial interactions of collagens and       
              Aggrecan in articular cartilage environment (Kiani et al. 2002). 
 
This gel-like substance is due to the numerous negatively charged anionic 
molecules on the GAG side chains within the ACAN protein that carry Na+ as counter  
positive ions.  This causes a significant disparity in ion concentrations between cartilage 
and the surrounding tissue resulting in diffusible free anions and cations to be out of 
balance.  This osmotic pressure draws water into the cartilage tissue due to ACAN’s size 
and bonded structure with other proteoglycans. 
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The ACAN core protein is composed of three domains designated G1, G2 and G3, 
and has attached numerous keratan sulphate (KS) chains with N- and O-linked 
oligosaccharides and a large region of chondroitin sulphate chains (CS) between the G2 
and G3 domains allowing glycosaminoglycan (GAG) side chain attachment post- 
translationally.  The link protein is a small glycoprotein that helps stabilize the overall 
structure formation and has a similar structural design to G1.  Whereby, the G1 globular 
domain of the protein located at the N-terminal end specifically binds to hyaluronan by a 
non-covalent bond with link protein (Heingard et al. 1974).  This is part of the tertiary 
structure complex within the ECM.  Situated between the G2 domain and G3 domain is a 
large sequence modified by KS side chains and CS chains. Each ACAN contains ~ 100 
chondroitin sulfate chains, which are typically ~ 20 kDa each. There are fewer keratan 
sulfate chains (up to 60) and they are usually of smaller size (5-15 kDa).  These chains 
combine to make up 90% of ACAN’s mass (Kiani et al. 2002). The G2 has tandem 
repeats which make it homologous to G1 and link protein.  G2 is separated from G1 by 
an interlobular domain (IGD) and is involved in processing product (Fosang et al. 1989; 
Paulsson et al. 1987).  Located on the C-terminus end within the G3 domain are two 
epidermal growth factor-like sections, EGF1 and EGF2.  Other sites include a 
carbohydrate recognition domain (CRD), complement binding protein (CBP)-like sites, a 
folded immunoglobulin region and tandem repeats of proteoglycan (Perkins et al. 1989).  
Figure 1.2 shows the globular and domain structures of ACAN. 
 
Sequence conservation is very high within the three globular domains (G1, G2, 
and G3) of known ACAN sequences across species, including humans.  The regions of 
chondroitin sulfate chains and keratan sulfate chains are less conserved across species.  
There is a strong correlation between exon number sequence and structure domain layout 
of ACAN.  This is most evident in that the chondroitin sulfate chain domain is specific to 
a single exon (Kiani et al. 2002).  Exon 1 encodes a 5’ end sequence that is untranslated 
and exon 2 contains a translation start codon site for protein synthesis.  G1 domain is 
divided into loop sections of A, B, B’ and correspond to subsequent exons 3, 4 - 5, and 6, 
respectively.  Link protein exons 3, 4-5, 6 correspond to the G1 loop sections in sequence 
similarity confirming binding site affinities (Valhmu et al. 1995).  The G1 domain is 
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comprised of three modules: an immunoglobulin fold module and two copies of an HA-
binding link module, this is also referred to as the PTR or proteoglycan tandem repeat.  
The G1 domain is also comprised of two cysteine-rich motifs that form disulfide bonds.  
These disulfide bonds are involved in ACAN interactions with HA to form large 
complexes (Watanabe et al. 1998). 
 
The rod shaped structure separating the G1 and G2 domains is the interglobulin 
domain (IGD).  The IGD is encoded strictly by exon 7 of the gene ACAN.  This structure 
and sequence is unique to the ACAN molecule.  Interestingly, during pathological 
cartilage degradation, this is the area of proteolytic attack by Aggrecanase-1 at the 
Glu373-Ala374 bond.  This appears to be the site of ACAN turnover physiologically 
(Tortorella et al. 1999). Matrix metalloproteinases (MMP) and Aggrecanase-1 are both 
believed to be involved in ACAN molecule turnover in both diseased and normal cartilage 
(Lark et al. 1997). 
 
The G2 domain involves exons 8, 9, 10 of the gene.  There are two tandem 
repeats of proteoglycan that are about 67% similar in sequence to the G1 PTR repeats, 
however, it shows no functional ability to bind with HA-binding ability with link protein 
possibly due to karatan sulfate side chains (Fosang et al. 1991).  Interestingly, ACAN is 
the only proteoglycan family member that has this G2 sequence and structure domain.  
ACAN is also the only proteoglycan family member with the keratan sulfate and 
chondroitin chains that make this protein highly glycosylated.  The G2 domain presently 
is thought to only function as a quality control domain in producing a mature working 
ACAN protein (Kiani et al. 2001). 
 
The (KS) keratan sulfate domain, encoded by exon 11 in humans, follows the G2 
domain.  This sequence of amino acids makes up a group of tandem repeat chains which 
varies in number greatly across species.  Rats, mice and chicken (Krueger et al. 1990) 
lack this repeat sequence region, however; bovine (Antonsson et al. 1989), human 
(Doege et al. 1991) and horse seen in this current study, contain these sequences in 
various amounts and in a strikingly similar repeat fashion.  This hexamer sequence 
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contains proline-serine and proline-threonine repeats suggesting this region as possible 
candidate areas for KS chain substitution.  Humans contain additional residue sequences 
of 66 highly conserved hexamer motifs repeated 11 times.  This confirms the human 
sequence is more glycosylated than the rat or bovine which contain less repeats.  The KS 
region is not unique within the ACAN core protein.  KS attachments also occur within the 
CS chains by being oligosaccharide linked to threonine (Hopwood et al. 1974).  A KS 
structural characteristic seen in differing cartilage tissue sources within an organism is 
most noticeably between non-bearing and load-bearing cartilage.  KS chains in joints that 
are load-bearing contain 1-3 fuctose residues and 2-6 N-acetyl neuraminic acid residues 
unlike cartilage in the nose (Nieduszynski et al. 1990).  Another unique characteristic to 
keratan sulfate chains within human meniscus is that, as humans age the KS chains and 
the 6-sulfated disaccharide of chondroitin sulfate chains increase in concentrations 
(McNicol et al. 1980).  The complete function of the keratan sulfate chains are not 
known, however it is suggested that they may contribute to tissue development, 
processing and distribution.  The one important characteristic of the KS chain is the 
binding of water molecules within ACAN, significantly enhancing the ECM’s ability to 
handle load bearing stress (Kiani et al. 2001). 
 
Chondroitin sulfate (CS) region is ACAN’s largest domain.  It is solely encoded 
by exon 12 in humans with a product size of approximately 3.5 kb.  The domain includes 
dipeptide repeats that contain serine-glycine residues and are separated by acidic and 
hydrophobic residues frequently (Krueger et al. 1990).  CS chain recognition sites for 
attachment have been suggested to be S-G-X-G (Bourdon et al. 1987) or (D/E)-X-S-G 
(Krueger et al. 1990).  There is some thought that these recognition sequence sites are 
dependent on chaperone proteins and the presence of specific enzymes that are necessary 
for post-translational modifications.  The chief role of ACAN as a structural ECM 
proteoglycan is to hold water within the ECM.  This is accomplished by the large number 
of negatively charged CS chains.  The glycosaminoglycan (GAG) chains may play a vital 
role in ACAN processing because of their similar property characteristics of holding water 
within the ECM.  This role in ACAN processing and secretion has been shown by the 
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addition of GAG chains to the CS region.  Without these GAG modified CS sequences, 
CS containing constructs are not secreted (Kiani et al. 2001). 
 
GAG chain modification is dependent on the G3 domain.  This domain is highly 
complex involving alternative splicing of exons post-transcriptionally. In human ACAN it 
consists of two alternatively spliced EGF-like domains encoded by exons 13 and 14, a C-
type Lectin-like domain also called LEC-like domain (also referred to as CRD module) 
encoded by exons 15, 16, and 17.  An alternatively spliced CRP-like domain (also 
referred to as CBP module) is encoded by exon 18 (Doege et al. 1991; Fulop et al. 1993).   
In humans only about a quarter of the EGF-l like domain gets translated and a small 
portion contain the EGF-2 like domain or both (Fulop et al. 1993), due to variable 
alternative splicing.  In rats, mice and dogs the EGF-1 domain is not translated due it 
being part of an intron, and in chickens some of the ACAN molecules have one or even 
none of the EGF domains encoded by exon 14.  The C-type Lectin-like CRD are encoded 
by exons 14, 15, 16, 17 and the CBP/CRP domain in chickens encoded by exon 18 (Kiani 
et al. 2002).   The function of the CRP/CBP domain is to bind fucose and galactose 
(Halberg et al. 1988) as well as the processing of ACAN proven by nanomelia in chickens 
and cmd mice.  Without the G3 domain ACAN cannot be modified by GAG and this 
unmodified core protein cannot be secreted by the cell.  It has been shown that in chicken 
ACAN the G3 domain’s major functions involve the LEC-like/CRD domain encoded by 
exon 15.  These animal models propose the attachment of GAG chains are modulated by 
G3 and this affects secretion from the cells (Kiani et al. 2001).  G3 in overall functions of 
ACAN processing, is an important factor in the control of quality ACAN secretion and 
breakdown through degradation pathways dependent on ubiquitin-proteosome control.  
This role shows the significant role the G3 domain plays in GAG chain attachment and 
facilitating ACAN secretion.  This is most notably controlled by the cysteine residues 
within the CRD/LEC-like and the CRP/CBP modules (Chen et al. 2002).  The most 
interesting feature of the G3 inter-domain dependent regulation controls is that GAG 
modification is separate from product secretion in that the modification of the GAG 
matrix formation overrides its effect to the secretion of ACAN but not vice-versa (Kiani et 
al. 2002).  The G3 domain as a whole could be involved in other aspects of ACAN 
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production, modification and degradation as seen with other proteoglycans like versican, 
however; no studies to date shown this to be the case. 
 
 
Figure 1.2. Aggrecan structure 
(A) Globular protein and attached GAG chain structure. (B) Protein domain structure. 
Folded modules: IgG, immunoglobulin fold: TR, tandem repeats: EGF, epidermal growth 
factor-like module: CRD, carbohydrate recognition domain: CBP, complement binding 
protein-like module. Extended domains: IGD, interglobular domain: KS, keratan sulfate 
attachment domain: CS-1 and CS-2, chondroitin sulfate attachment domains (Kiani et al. 
2002). 
 
Purpose of Study 
The purpose of the study described in this thesis was to uncover the cause of 
dwarfism among Miniature horses. At the beginning of the study it appeared that multiple 
genes with mutations might be responsible for the condition and candidate gene studies in 
families were conducted to uncover which of the more than 200 genes causing dwarfism 
among people were responsible for the condition in horses.  However, the study revealed 
that most cases of dwarfism in Miniature horses were the consequence of one of at least 4 
mutations in the gene, Aggrecan (ACAN). 
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Chapter 2 
Disproportionate Dwarfism in Miniature Horses 
 
Summary 
 
 This chapter focuses on describing the protocols utilized and results in the 
discovery of the mutations in Aggrecan (ACAN) which are responsible for the majority of 
dwarfisms within the Miniature horse breed.  DNA samples were isolated from dwarfs 
and normal Miniature horses and select samples were sent to the Mayo Clinic for testing 
using the Illumina Equine SNP50 chip. The results were analyzed using PLINK which 
revealed a SNP with statistical significance near ACAN on chromosome 1 of the equine 
genome.  Subsequent sequencing of ACANindicated the existence of at least four separate 
recessive mutations that cause dwarfism.  These mutations are independently segregating 
within the population worldwide. Novel mutation combinations occur causing combined 
expression in heterozygote dwarfs of two different mutations.  Two of the mutations are 
deletions of a single base in exons 2 (D1) and 11(D3) causing a frameshift and presumed 
loss of function of the protein.  The exon 2 (D1) deletion causes lethality in homozygous 
form and in combination with any of the other mutations. Another mutation is a deletion 
of 21 bases in exon 15 (D4) causing a loss of 7 amino acids in the resulting protein and 
loss of reading frame. The last mutation is a single base substitution in exon 6 (D2) 
causing changes in amino acid in the resulting protein. The exon 6 (D2) mutation predicts 
a decrease in function of the resulting protein due to the intricate binding interaction of 
link protein and G1 domain of ACAN to produce a functional ECM.  During the 
sequencing process numerous non-causative SNPs were discovered within ACAN of the 
horse and are listed within this dissertation.  Custom Taqman® Assay Probes were 
designed for mutations in exons 2, 6, and 11.  A simple PCR of exon 15 and results run 
on a 2% agarose gel was the method used to test for the mutation in exon 15.Testing for 
dwarfisms D1 (exon 2), D2 (exon 6), and D4(exon 15) has been performed and 
completed on the entire sample population of Miniature horses and select large sized 
horse breeds.  However, testing for D3(exon 11) dwarfism has not been completed. 
 
22 
 
Introduction 
 
The main objectives of Miniature horse breeders are to produce small and 
proportionate horses.  However, selection for small size could result in selection for 
dwarfism.  With a foundation of immense genetic variation and no strict quality standards 
of bloodstock except height, some Miniature horse breeders utilized severely malformed 
small horses in breeding programs.  These conformationally inferior horses exhibited 
consistent physical abnormalities typical of disproportionate dwarfisms as seen in other 
mammal species.   
 
Other animal species with documented dwarfism include: dog, mouse, chicken, 
and cow.  Defects in over 200 genes have been found to cause dwarfism in humans.  
Defects in genes for humans can involve genes responsible for pituitary gland hormones, 
thyroid gland hormones,hormone production and/or recognition, metabolism, cartilage 
development and bone growth plate development.  During the course of the study it 
became apparent that the common forms of dwarfism in the Miniature horses fell into 
two groups. One group was characterized as Chondrodysplasia-like and were subject of 
this study.  This type of dwarfism involves malformations of the cartilage and subsequent 
maturation to bone during fetal development and subsequent growth of the individual 
during sexual maturation.  The other form of dwarfism seen in the Miniature horse 
population did not display Chondrodysplasia-like characteristics.  However, these 
individuals did exhibit slightly enlarged sized head and shortened upper leg bones, but 
normal lower leg length and normal size of body and neck.  This type of skeletal atavism 
is phenotypically similar to the dwarfism characterized in Friesians (Back et al. 2008).  
However, the cause of dwarfism among Friesian horses appears to affect only the long 
bones of the leg (skeletal atavism).  These individuals were not subject to this study and 
appear to have a different genetic basis (Orr et al. 2010; Lindgren, personal 
communication 2013).  The Miniature horse dwarfs displaying skeletal atavism are part 
of a study for this disease within the Miniature horse population (Rafiti et al. 2013).    
The dwarfism under study here causes disproportionate reduction of the entire individual.  
Disproportionate dwarfism involves the shortening and malformation of all the long 
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bones of the body and causes abnormal growth of the other bones within the body (i.e. 
skull).  Skeletal atavism is a disease that involves only specific bones of the body being 
shortened and the rest of the bones are left relatively unaltered and normal. 
 
Disproportionate dwarfism in Miniature horses, in decades past, has been a well-
known unspoken issue.  Its existence has been shown through anecdotal photo evidence 
and record keeping of breeders.  These horses with conformation typical of 
disproportionate dwarfism have significant health, quality of life and soundness issues.  
Many Miniature horse registries try to avoid accepting minis affected by dwarfism for 
breeding stock registration (AMHA 2012; AMHR 2012).  Unfortunately, these 
individuals are still used in breeding programs today.  Dwarfism is a problem for the 
horse breeder who wishes to produce a healthy, diminutive horse which has proportions 
and conformation similar to that of large horse breeds.  Therefore, this study was 
undertaken to uncover the gene(s) responsible for some types of dwarfism and develop 
diagnostic tests to guide breeders. 
 
Materials and Methods 
 
Horses used in Dwarfism Study 
Two hundred AMHA registered Miniature horses from private farms were 
phenotyped for dwarfism and hair, blood or postmortem tissue collected for DNA 
isolation.  Horses were selected based on a history of producing dwarfs or having a 
pedigree from known dwarf producers.  Pedigree information, if available, was attained 
through the studbook of the AMHA registry.  In addition, a total of 44 horses from the 
AMHR registry were tested but were of unknown phenotype for dwarfism.  These 
samples were acquired from the University of Kentucky DNA typing Laboratory.  Horses 
from other breeds which have not reported the occurrence of dwarf phenotypes were also 
tested which included 28 Thoroughbred, 22 American Standardbred, 4 American 
Saddlebred, 4 Tennessee Walking horses, 4 Arabian, 1 hackney pony and 1 Caspian 
horse.   
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Phenotyping 
Miniature horses normally have a small stature. Dwarfism is distinguished by 
exhibition of several of the following characteristics: severely shortened stature, 
shortened limbs relative to overall body size, bowed forelegs, shortened neck, 
disproportionately large cranium, flat faces with large bulging eye sockets with 
prominent eyes, low nasal bridge, severe under bite, retruded muzzle, cleft palate and 
protruding tongue and a large abdominal hernia, or embryonic loss. 
During the course of the study it became apparent that the common forms of 
dwarfism fell into two groups. One group was characterized as Chondrodysplasia-like 
and were subject of this study.   This type of dwarfism involves malformations of the 
cartilage and subsequent bone during fetal development and growth of the individual.  
The other form of dwarfism seen in the Miniature horse population did not display 
Chondrodysplasia-like characteristics.  However, these individuals did exhibit a slightly 
enlarged head and shortened upper leg bones, but normal lower leg length and normal 
size of body and neck.   
 
DNA Isolation 
DNA from blood or tissue was extracted using Puregene whole blood DNA 
extraction kits (Gentra Systems Inc., Minneapolis, MN) and Puregene tissue DNA 
extraction kits according to published protocols.  Hair samples submitted were processed 
using 7-10 hair bulbs according to the method described by Locke et al. (2002).  The hair 
bulbs were placed in 100 µl lysis solution containing 1X FastStart Taq Polymerase PCR 
buffer (Roche), 2.5 mM MgCl (Roche), 0.5% Tween 20 (JT Baker, Phillipsburg, NJ) and 
0.01 mg proteinase K (Sigma-Aldrich, St. Louis, MO) and incubated at 60°C for 45 
minutes followed by 95°C for 45 minutes to deactivate the proteinase K.  Aliquots of the 
DNA samples were made for working dilutions at concentrations of approximately 150 
ng/µl. 
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Illumina Equine SNP50 Testing 
DNA samples at concentrations of 150 ng/µlfrom 46 horses were selected for 
testing with the Illumina Equine SNP50 chip.  Of the 46 samples, 20 were from horses 
characterized as dwarves while the remainder were from Miniature horses with normal 
appearance.   Among the 26 normal phenotype horses, all 26 were related to 6 of the 
affected horses as sibling or as parents.  DNA samples were tested at the Mayo Clinic 
under the auspices of a Morris Animal Foundation Grant awarded to the University of 
Minnesota.  The DNA samples were tested by the Mayo Clinic and results returned for 
analysis.   
 
PLINK Analysis 
PLINK (Purcell et al. 2007) was used for analysis of the data.   The Illumina 
SNP50 chip assayed for 59,349 SNPs.  The entire call rate was greater than 95% for all 
46 horses so all 46 were retained for analyses.   SNPs were eliminated from the analyses 
when the minor allele frequency (MAF) was less than 0.05 and the call rate for the SNP 
(GENO) was less than 90%.  As a consequence, analyses included 40,368 SNPs.  The 
data for dwarf horses was designated as cases and the data for normal horses was 
designated controls.Association study with a Monte Carlo based approach (5000 
permutations) was run to compare differences in the occurrence of SNPs among the case 
and control horses. The permutation option (EMP2) corrected for the large number of 
comparisons being made.  P-values less than 0.05 for EMP2 were considered significant 
and the region selected for further analyses.  The SNPs from the region with statistical 
significance were further tested using the hap-phase option to identify haplotypes 
associated with the trait and to deduce the mode of inheritance.    
 
GWAS 
The only SNP that achieved statistical significance based on EMP2 score was 
BIEC2_38994 with a P- value of 0.003 found on ECA1.  Below is Figure 2.1 identifying 
ECA 1 at SNP BIEC2_38994.  See Appendix for supplementary Table 2.S1 SNPs with 
the highest EMP2 scores.   
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Figure 2.1. Graph displaying Max-T permutation quantification analysis showing 
statistical significance of SNP BIEC2_38994 on chromosome 1.  
 
 
Haplotypes of individual dwarf samples within the GWAS study were compared 
using the Hap-Phase option within PLINK. These haplotypes associated with dwarfism 
showed at least 4 different haplotypes involved in the frequency differences between the 
controls and the affected horses. Furthermore, most of the dwarf individuals were 
heterozygous for these haplotypes.  If a single recessive mutation were responsible for 
dwarfism, we would have expected to find homozygosity for a single haplotype among 
the affected horses.  See Appendix for supplementary Table 2.S2 for haplotype 
association with dwarfs and controls. 
 
The region possessing these statistically associated SNPs includes a gene-
homologue known to cause dwarfism among human, mice, chicken and cattle, namely 
ACAN.  In genome assembly Ecab 2.0, this gene was reported between 94,344,146 and 
94,381,944; the associated SNP BIEC2_38994 is located at 94,215,030 on ECA 1.  This 
is approximately 129,000 bp downstream of ACAN(XM_001917528.2) shown in Figure 
2.2.   
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Figure 2.2.  UCSC Genome Browser on Ecab 2.0 shows location of AGC1 (ACAN) in 
relation to SNP BIEC2_38994 129,000 bp downstream. 
 
 
DNA Sequencing 
A candidate gene, specifically ACAN, was identified near the region of highest 
statistical significance.  Therefore, sequencing studies were begun to determine whether 
mutations in this gene might cause dwarfism among these horses.  Evaluating predicted 
exon information from UCSC, Ensembl and NCBI, discrepancies were noticed in 
predictions of number and location of exons for equine ACAN.  The various databases 
showed discrepancy with regard to exon 11 and 12 and an unexpressed yet in silico 
predicted exon in NCBI.  Therefore to simplify, all exon descriptions will be based on 
NCBI count with regards to exon count shown in Figure 2.3.  
 
 
Figure 2.3. NCBI In Silico genome location, number and size prediction of exons for 
equine ACAN. 
 
Once exon expression accuracy was determined specific exon primers were 
designed.  Exons for ACAN were amplified by PCR (see Appendix for primers used for 
SNP BIEC2_38994 
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exons in supplementary Table 2.S3).  PCR Template for sequencing was amplified in 20 
µl PCR reactions using 1X PCR buffer with 2.0 mM MgCl₂, 200 µM of each dNTP, 150 
ng genomic DNA from hair, blood or tissue extractions, 0.2 µl FastStart Taq DNA 
polymerase (Perkin Elmer) and 50 nM of each primer.  Each exon template PCR product 
was quantified on a 2% agarose gel run in 1X TBE solution and then amplified using the 
BigDye Terminator v1.1 cycle sequencing kit according to manufacturer’s instructions 
(Applied Biosystems, Foster City, CA).  Resulting sequence product was cleaned using 
Centri-Sep columns (Princeton Separations Inc., Adelphia, NJ), and read on an ABI 310 
genetic analyzer (Applied Biosystems).  At least six samples were initially sequenced for 
each exon: two dwarf samples, two parents of the dwarf samples and two non-dwarf 
producing samples.  The non-producing samples were stallions with at least 100 
registered foals with AMHA and no known dwarfs among the offspring.  The results 
were analysed using Vector NTI Advance 10.3 software package using ContigExpress 
alignment program (Invitrogen Corporation, Carlsbad, CA).  Exon sequencing identified 
SNPs and deletions described in this and the subsequent chapter. 
 
Custom Taqman® Assay Probes 
Three of the DNA variants identified associated with the occurrence of dwarfism, 
exon 2, exon 6, and exon 12 were chosen for custom Taqman® probe assays. To assay 
the presence of these variants among other normal and dwarf horses, including horses of 
other breeds, custom Taqman® SNP Genotyping Assays (Applied Biosystems) were 
designed for the three variants; exon 2 deletion c. 245(A/-) SNP and exon 6 c. 1270(G/A) 
c. 1290 (C/T) SNP; and exon 12 c. 6700 (C/-) deletion, in Filebuilder 3.1 software 
(Applied Biosystems) to test the population distribution of these three sets of independent 
variants.  These assays were run on a 7500 HT Fast Real Time-PCR System (Applied 
Biosystems).  The fourth variant, exon 15 with a 21 bp deletion, was simply amplified by 
PCR for the exon template and the PCR product was quantified on a 2% agarose gel to 
determine existence sequence size variant. 
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RESULTS 
 
Genotype Variants  
ACAN exons were sequenced and compared among dwarf and non-dwarf 
individuals.  The sequence data for exonic regions was compared to the Reference 
sequence entry for equine ACAN (XM_001917528.2) using the reference Equus caballus 
2.0 from NCBI whole genome shotgun sequence using sequence viewer 2.24.  Initially, a 
SNP in exon 6 associated with homozygosity for dwarfism was found. When a significant 
number of the dwarf individuals appeared to be heterozygotes for this mutation,ACAN 
exons were sequenced on some of those dwarfs resulting in discovery of additional 
frameshift or non-synonymous mutations which may alter gene expression or function.  
Table 2.1 identifies 4 DNA variants identified as likely causes of dwarfism based on two 
criteria: 1) the DNA change was predicted to have a significant effect on the function of 
the protein, and 2) investigations of normal horses and horses with chondrodysplasia-like 
dwarfism showed a complete association between genotypes for these variants and 
theoccurrence of dwarfism. 
 
Table 2.1. DNA Variants for Dwarfism. Position of mutation on NCBI Equus caballus 
build 2.0 with reference WT allele and mutant allele with resulting effect. 
Allele Effect Position (build 2.0) Reference allele Mutant allele
Acan-N normal
Acan-D1 recessive dwarfism 94,379,389 A  -
Acan-D2 recessive dwarfism 94,372,649 G A
Acan-D3 recessive dwarfism 94,358,998 C  -
Acan-D4 recessive dwarfism 94,346,122- 94,346,102 CGTGGTGATGATCTGGCACGA  -
 
Table 2.1(continued). DNA Variants for Dwarfism. Exon position of mutant allele 
cDNA base change and numbered position in gene and resulting numbered protein 
produced by mutant allele from WT. 
Allele Effect Exon cDNA XM_001917528.2 Protein
Acan-N normal
Acan-D1 recessive dwarfism exon 2 c.245del A p.K82fx
Acan-D2 recessive dwarfism exon 6 c.1270G>A p.V424M
Acan-D3 recessive dwarfism exon 11 c.6700delC p.P1875fx
Acan-D4 recessive dwarfism exon 15 c.7299-7319del p.F2433-O2440del
 
Allele designations for mutations involving ACAN were made as follows:  ACAN-
N wasused for the normal, non-dwarf form of ACAN; ACAN- D1, D2, D3 and D4 were 
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used for the four mutations identified and associated with dwarfism.  Hereafter, the 5 
alleles are referred to as N, D1, D2, D3 and D4. 
Four DNA variants were identified which appeared associated with unique 
dwarfism types seen in the breed.  A single base deletion in NCBI exon 2 (D1), a single 
SNP substitution in NCBI exon 6 (D2), a single base deletion in NCBI exon 11 (D3) 
(UCSC exon 12) and a 21 base deletion in NCBI exon 15 (D4) (UCSC exon 15) were the 
four mutations found.  In each case, the mutations would have resulted in a frame shift 
resulting in altered expression or loss of expression of ACAN or an amino acid 
substitution which may have altered function.  In addition to the predicted effects of the 
mutation, we observed association of the mutations with the occurrence of the dwarf 
condition.  Table 2.2 shows the genotypes with phenotype descriptions for the 5 ACAN 
alleles (N, D1, D2, D3, and D4).   
 
Table 2.2. Genotype/phenotype descriptions. General descriptions of the five alleles of 
ACAN including novel combinations and resulting phenotype. 
Genotype Phenotype
N/- normal, no dwarfism
D1/D1  Horses with this genotype were early gestational lethal dwarf
D1/D2  Horses with this genotype were early gestational lethal dwarf
D1/D3  Horses with this genotype were early gestational lethal dwarf
D1/D4  Horses with this genotype were early gestational lethal dwarf
D2/D2 Horses with this genotype were dwarf
D2/D3  Horses with this genotype were dwarf
D2/D4 Horses with this genotype were dwarf
D3/D3  No samples of this genotype, possibly due to sampling size
D3/D4  Horses with this genotype were dwarf
D4/D4 No samples of this genotype, possible early gestational lethal dwarf  
 
Table 2.3 shows the genotype and associated phenotype count within the samples 
with regard to the presence or absence of dwarfism or fetal loss.  The dwarfs with 
genotype N/N and N/D2 were not the Chondrodysplasia type and may represent the form 
seen in Friesian horses with normal bodies and shortened legs referred to as skeletal 
atavism.   The testing results of these dwarfs with skeletal atavism being heterozygous for 
one of the mutations within ACAN shows convincing evidence that skeletal atavism is not 
in linkage disequilibrium with any of the mutations found.Data shown in Table 2.3 
illustrate the number of individual genotypes categorized within the population of 
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samples gathered.  This table demonstrates the genotypes for normal and heterozygous 
normal carriers of the four dwarf alleles are all within the normal genotype group of the 
population sampled.  No homozygous normal or heterozygous normal carrier genotyped 
individuals exist within any grouping of homozygous dwarf alleles nor in novel dwarf 
allele combinations.   
 
Table 2.3. Genotype Association Studies. 
 * refers to individuals that display skeletal atavism type dwarfism 
 # refers to some individuals not typed yet for D3/D4 or N/D3 from the Sample 
population 
** refers to no samples collected that are homozygous D3/D3 or D4/D4 from the sample 
population 
  Physical Manifestations
Genotypes  Term live dwarf Nonviable/Aborted Dwarf  Normal
N/N *1 0 66
N/D1 0 0 27
N/D2 *3 0 39
N/D3 #0 #0 #0
N/D4 0 0 2
D1/D1 0 1 0
D1/D2 0 9 0
D1/D3 0 2 0
D1/D4 0 1 0
D2/D2 17 1 0
D2/D3 11 1 0
D2/D4 5 0 0
D3/D3 **0 **0 0
D3/D4 #3 #0 0
D4/D4 **0 **0 0  
 
 
Genotypes and Qualitative Assessment of Phenotypes 
Physical characteristics of four unique and distinct dwarf phenotypes observed 
within the Miniature horse breed were categorized and characterized.   Once proposed 
causative mutations were found, homozygous dwarf individuals were either physically 
examined or examined via multiple photos to assess common abnormal characteristics for 
each phenotype to match and confirm genotype.  A population group of 200 AMHA 
Miniature horses were tested for evidence of heterozygosity of proposed mutations to 
confirm that normal carriers only possessed one copy of any given proposed mutation.  If 
available, parents of dwarfs with homozygous results or novel combinations were tested 
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to confirm inheritance of specific mutations from each carrier parent to resulting dwarf 
foal.  Miniature stallions with known offspring numbers statistically sufficient to qualify 
as a non-carrier were tested for lack of evidence of mutations for confirmation.  In 
addition, a total of 44 Miniature horses from the AMHR registry were tested but were of 
unknown phenotype for dwarfism.  The testing results of 44 random horses from the 
AMHR registry were of unknown phenotype for dwarfism.  None of these tested 
homozygous for any of the proposed causative mutations or novel combinations thereof; 
however two tested as heterozygous carriers for the D2 allele (N/D2).  No other AMHR 
horses tested positive as carriers for any other dwarf allele.  More testing needs to be 
performed in both AMHA and AMHR populations, however; from the limited data 
collected, AMHR horses have a much less incidence of carriers of dwarf alleles 
compared to the AMHA population.   
 
A panel of other horse breeds was tested for the existence of any of the proposed 
causative mutations.  Horses from other breeds which have not reported the occurrence of 
dwarf phenotypes included 28 Thoroughbred, 22 American Standardbred, 4 American 
Saddlebred, 4 Tennessee Walking horses, 4 Arabian, 1 hackney pony and 1 Caspian 
horse.  These 64 large horse samples tested negative for dwarf alleles D1, D2, and D4, 
however; they have not been tested for allele D3 as of this writing.  Results are shown in 
the Appendix in Table 2.S4. 
 
Genotypes with D1 
Genotypes involving D1 in combination with any other mutant allele appeared to 
be fetal lethals.  Miniature dwarf genotype D1/D1 is characterized as showing fetal 
abortion.  Growth is extremely small stature, disproportionate dwarfism with a cranium 
large and domed for gestational age, extremely low nasal bridge, and extreme 
micrognathiawith severely retruded muzzle, cleft palate and protruding tongue.  
Characteristic ears set low and to the rear of cranium and large bulging eyes.  Neck 
appears to be almost non-existent even in early gestation.  Trunk involves a large 
abdominal hernia andextremely short vertebral column with ribs extremely short and thin.  
Limbs show severe micromeliaand appear to involve changes in limb bones that are 
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consistent with failure of endochondral ossification.  All bones are poorly ossified for 
gestational stage.  Figure 2.4 A, B, C show typical phenotype. When novel combinations 
of D1 allele occur with other ACAN dwarf alleles, the resulting fetus is also lethal.  Figure 
2.5 A, B, C show novel heterozygous lethals. 
 
 
 
A.           B.                                  C. 
Figure 2.4 A, B, C. Fetus dwarfs homozygous for genotype D1/D1. 
 
 
 
A.             B.                               C. 
Figure 2.5 A. Genotype D1/D2.  B. Genotype D1/D3.  C. Genotype D1/D4. 
 
Genotypes with D2 
Horses inheriting the D2 allele and D2, D3 or D4 were viable.  Miniature dwarf 
genotype D2/D2 is characterized with disproportionate short stature with short barrel 
shown in Figure 2.6 A, B, C.  Craniofacial has a disproportionately large head with 
pronounced frontal bone domed prominence, enlarged eyes and orbit with a low and 
severely shortened nasal bone with retruded muzzle and under bite of varying severity.  
Airway obstruction develops and it is possible to be "central" in origin (due to foramen 
magnum compression) or "obstructive" in origin (due to narrowed nasal passages), 
necropsies were inconclusive. Symptoms of airway obstruction include snoring and 
laboured breathing.  Limbs are short and thick comparatively to similar aged normal foal 
with various ranges of leg bowing due to joints.  Joints are enlarged at birth with limited 
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joint mobility and flexation.  Flexion contractures of hips, small pelvis size for overall 
size with rotation (goose rump).  A pronounced shortened neck is noticeable at birth.  The 
development of slight roach back and variable stiffness occurs with age.  The barrel 
appears shortened due to slight curvature of spine.  Motor milestones are often delayed 
secondary to joint deformities. Joint contractures and roach back progress with age. 
Progressive and painful joint enlargement can be accompanied by flexion contractures in 
all limb joints causing abnormal hoof growth very early.  Muscle atrophy results from 
disuse.  Novel combinations of D2 allele with other ACAN dwarf alleles express both 
mutations’ characteristics are shown in Figure 2.7 A, B, C. 
 
 
A.            B.                    C. 
Figure 2.6 A, B, C.  Dwarfs homozygous genotype D2/D2. 
 
 
 
A.           B.                  C. 
Figure 2.7A. Genotype D2/D3.  B. Genotype D2/D4.  C. Genotype D2/D1 
 
Genotypes with D3 
Offspring with D3 plus the D2 (described above), D3 and D4alleles were viable.  
The samples collected did not demonstrate any homozygous Miniature dwarf genotype 
D3/D3.  This is possibly due to sample size of the population, however the number of 
samples found with this mutation was quite small and it is considered a rare mutation.  
The homozygote D3at this time is not considered a lethal due to novel combinations 
being viable, however; it is lethal with D1.  A Dwarf with D3/- genotype is characterized 
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as disproportionate short stature with mature characteristics less severe than genotype 
D2/D2. Craniofacial structures are disproportionately large head with relative frontal 
bone slight domed prominence, enlarged eyes and orbit with a low and relatively 
shortened nasal bone, some show a retruded muzzle and generally have an under bite but 
not always.  Limbs showrhizomelicshortening usually with bowed forelegs with enlarged 
joints and thick long bones at birth, limited joint flexion predominantly affecting the 
knee, stifle, pastern and hock joints initially.  Progressive joint contractures of the pastern 
cause abnormal hoof growth with age.  The development of a progressive roach back and 
hip rotation occur with a relatively shortened neck.  Airway obstruction develops early 
and progresses with age.  Muscle atrophy results from disuse.  Novel combinations of D3 
allele with other ACAN dwarf mutations express both mutations’ characteristics are 
shown in Figure 2.8 A, B, C. 
 
    
A.         B.                C. 
Figure 2.8. A. Genotype D3/D2  B. Genotype D3/D4  C. Genotype D3/D1  
 
Genotypes with D4 
No samples of homozygous D4 mutation were acquired.  Only physical samples 
acquired were of novel combinations of other abnormal genotypes expressing both 
physical characteristics of each mutation. When D4 allele was present with D1 allele 
genotype, the results are lethal.  Growth wasdisproportionate, exhibitingsevere short 
stature with a short barrel misshapen and more pronounced than D2/D2 and D3/D3.  
Roaching of spine is more pronounced and severity progresses with age.  Barrel appears 
even more shortened due to curvature of spine.  Variable pain and stiffness of hip and 
limbs are progressive.  Craniofacial structures are disproportionately large head with 
pronounced frontal bone domed prominence, enlarged eyes and orbit with a low and 
shortened nasal bone with some having a retruded muzzle and under bite with varying 
severity.  Airway obstruction is evident early and progressive.  Limbs are rhizomelic in 
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length with bowing and joints are enlarged at birth with limited joint mobility.  Flexion 
contractures of hips, small pelvis with severe rotation (goose rump).Severely shortened 
neck is noticeable from birth that is almost nonexistent.  Motor milestones are often 
delayed secondary to joint deformities. Joint contractures and roach back progress 
quickly with age. Progressive and painful joint enlargement can be accompanied by 
flexion contractures in all limb joints causing abnormal hoof growth very early.  Muscle 
atrophy results from disuse some examples are shown in Figure 2.9 A, B, C.  
 
   
A.              B.        C. 
Figure 2.9 A. Genotype D4/D2.  B.Genotype D4/D3.  C.Genotype D4/D1  
 
 
Discussion 
 
Dwarfism within the Miniature horse breed has had various descriptions and 
terminology anecdotally used to characterize the various phenotypes observed.  Many 
medical terms used have been incorrectly or only partially utilized in describing specific 
characteristics of an observed phenotype.  When it was determined that ACAN was the 
gene involved in the dwarf types in this study, a concise yet encompassing descriptive 
term for these mutations was needed.  Other dwarfisms involving ACAN of other 
mammal species were referenced when deciding to describe the complexity of this 
disease within the Miniature horse.  Once it was discovered that multiple different 
mutations are independently segregating within the Miniature horse population and that 
these mutations produced specific distinct phenotypes in homozygotes, an inclusive term 
was necessary as a general descriptive term.  Work in Dexter cattle dwarfism revealed 
multiple different mutations within ACAN that definitively showed causation of that 
disease (Cavanagh et al. 2007).  The homozygous dwarf phenotype of Chondrodysplasia 
in the Dexter is similar to the Type D1/D1 seen in the Miniature horseexpressing 
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identical gross anatomical deformities as shown if Figure 2.10 A and 2.10 B.  In both the 
Dexter and the Miniature horse, the affected individuals of this phenotype are lethal and 
involve the same gene ACAN.  Chondrodysplasia in general is a term used to describe 
abnormal growth of cartilage. It causes disproportionate dwarfism and occurs as an 
inherited trait.  These mutations found within ACAN of the Miniature horse are 
Chondrodysplasia-like deformities of the cartilage causing subsequent abnormal growth 
and maturation of bone.  Therefore these four dwarf types observed to occur in an 
inherited form in the Miniature horse are designated Chondrodysplasia-like dwarfisms. 
 
                                   
Figure 2.10.A. Miniature                              Figure 2.10.B. Dexter lethal  
Lethal D1/D1                                                 chondrodysplasia dwarf 
                                                                       (Cavanagh et al. 2007) 
 
Skeletal atavism is another distinct type of dwarfism in the Miniature horse that 
had known to exist in Welsh and Shetlands previously (Tyson et al. 2004), see Figure 
2.11A. However, pathology of skeletal atavism is much different than the 
Chondrodysplasia-like dwarfism in this study.  Skeletal atavism is abnormal bone growth 
specifically restricted to the upper limb bones of the Miniature horse.  This type is quite 
similar in phenotype to Osteochondrodysplasia seen in Friesians(Bach et al. 2008), see 
Figure 2.11B. It is noted in the results that Miniature dwarfs of this type (skeletal 
atavism) were tested for the presence of any of the causative mutations within ACAN.  
The dwarfs with genotype N/N and N/D2 (Table 2.3) were of the skeletal atavism type.  
The testing results of these dwarfs with skeletal atavism being heterozygous for one of 
the mutations within ACAN shows convincing evidence that skeletal atavism is not in 
linkage disequilibrium with any of the mutations found. 
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Figure 2.11A. Miniature with                 Figure 2.11B. Friesian dwarf exhibiting  
Skeletal Atavism                                      Osteochodrodysplasia. (Back et al. 2008) 
 
Testing results showed that three skeletal atavism dwarfs were heterozygous 
carriers of D2.  No skeletal atavism dwarfs were homozygous for any of the proposed 
causative mutations of Equine Chondrodysplasia-like dwarfism in the Miniature horses.  
This gives convincing evidence these two types of dwarfisms are caused by two separate 
and independently segregating genes in the population.  The Miniature dwarfs displaying 
skeletal atavism are part of a study for this disease within the Miniature horse population 
(Rafiti et al. 2013).   
 
Sequence databases used for reference of Equine ACAN revealed discrepancies 
with regards to predicted exon number and location.  UCSC genome browser predicted 
an intron in exon 11 that included a major portion of the ~2400 bp repeat region, thus 
separating this sequence region into two exons (11 and 12) with the repeat region as the 
intron in between the two exons.  NCBI sequence viewer however, predicted exon 11 to 
be the entirety of UCSC exon 11, including the intron repeat region and exon 12.  NCBI 
also predicted another exon downstream of exon 11 as the next exon (NCBI exon 12).  
The UCSC genome browser did not predict NCBI exon 12 to exist as an exon and 
predicted this region to be an intron.  Expression data showed that NCBI correctly 
predicted exon 11 to be one exon that included the repeat region (UCSC exon 11, intron 
region and UCSC exon 12).  However, NCBI incorrectly predicted an exon 12 (exon does 
not exist in UCSC genome browser) that is not expressed.  The location of this NCBI 
predicted exon in the UCSC genome browser is in intron 12.  Therefore from this 
information, it is possible that the number of exons expressed is variable with splicing 
occurring during processing within the equine ACAN, as what has been shown to occur in 
humans and other mammal species (Valhmu et al. 1995).  The current count of expressed 
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exons in the genome databases is to exon 11 using NCBI predicted equine ACAN.  After 
which, the next exon expressed is UCSC exon 13 through exon 17.  NCBI denotes the 
same as UCSC with regards to exons 13 through 17.    
 
No studies in pathology have been conducted at this time.  Gene expression data 
at the cellular level and protein function data of ACAN within the ECM involving these 
proposed mutations were not examined.  Predicted loss of function is evident with 
deletions in exons 2, 12, and 15, for genotypes D1, D3 and D4respectively, causing 
subsequent frameshifts resulting in novel protein products.  Other published mammal 
mutations of ACAN involving deletions in various exons provide ample evidence of cause 
and effect (Watanabe et al.1997; Cavanagh et al.2007) as well as the sequence data from 
the Miniature horse samples with these mutations.  No Miniature horse samples with 
normal phenotypes were homozygous for any of these deletions, nor were there any 
normal phenotypes with genotypes of novel deletion combinations. 
 
The mutation in exon 6 involving a single base missense producing a change of 
amino acid valine to methionine causes the addition of a sulfur group.  The compelling 
argument for this to be causative is that no samples in the Miniature horse population 
tested possessed this D2 allele in homozygous form and a normal phenotype.  All novel 
combinations of D2 genotype with other dwarf genotypes (D1, D2, and D4) produced 
dwarf phenotypes.  All parents of D2/D2genotype dwarf samples matched as 
heterozygous carriers with the causative missense sequence for this genotype.  The 
published information regarding function of this exon is that link protein and its exons are 
complimentary to ACAN in structure and binding function at the exon sequence level.  As 
mentioned, the G1 domain of ACAN is divided into loop sections of A, B, B’ and 
correspond to subsequent exons 3 (A), 4 – 5 (B), and 6(B’), respectively.  Link protein 
exons 3-6 correspond to the G1 loop sections in sequence similarity confirming binding 
site affinities (Valhmu et al. 1995).  There is no information regarding mutations in 
ACAN G1 or Link protein in humans, inferring the importance of the aggregate formation 
of ACAN and the ECM in skeletal development (Aspberg et al. 2012).  The existence of a 
valine to methionine missense mutation in the C-type lectin domain (CLD) of the G3 
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domain of ACAN causing a type of dwarfism in humans (Stattin et al. 2010), leads to the 
possibility of a similar situation with the valine to methionine mutation in exon 6 of the 
Miniature horse.  This information provides evidence that this missense likely causes 
incomplete or loss of binding ability betweenACAN and link protein to properly form the 
ECM.  The sequence data of Miniature horse samples also shows high conservation of 
exons 3, 4, 5 and 6 with complete conservation in exons 3 or 4, one synonymous SNP in 
exon 5, and exon 6 containing two non-causative SNPs changing amino acid sequence 
and one synonymous SNP.  This confirms known sequence data across species of high 
sequence conservation in this region (Valhmu et al. 1995). 
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Chapter 3 
Polymorphisms of ACAN Not Found to Cause Dwarfism 
 
Summary 
 
 Single nucleotide polymorphisms, referred to as SNPs, are the result of mutations 
that occur through genetic evolution of a species within its environment.  These 
mutations sometimes produce a change in a resulting protein that makes it advantageous 
to the species.  Other times the mutation may be deleterious and the resulting protein has 
a partial or complete loss of function.  However, there are also times synonymous 
mutations occur resulting in no change of the resulting protein.   These mutations may or 
may not alter the resulting phenotype of an individual.  Polymorphisms allow a species to 
genetically maintain variability in its environment.  This presumably gives the species a 
better chance of survival if that environment were to change.   
During the course of investigating dwarfism in the Miniature horse and 
sequencing the gene responsible, ACAN, numerous SNPs were discovered that did not 
appear annotated in the reference sequence noted in this chapter.  No SNPs causing a 
change in amino acid sequence exhibited linkage disequilibrium with any known dwarf 
phenotype investigated.  However, some synonymous SNPs displayed linkage 
disequilibrium with specific dwarf phenotypes.  Various numbers of DNA samples were 
sequenced for each exon to initially look for mutations causing dwarfism.  When 
numerous SNPs were noted, certain specific individual samples were sequenced through 
most, if not all, of the exons.  Some of these samples were dwarfs already determined 
homozygous for a specific mutation, and other samples were stallions that were 
considered statistically normal for all dwarf types due to the number of registered 
offspring and never producing a dwarf.  However, not all samples acquired were 
sequenced entirely or at all and were only tested for genotype status of mutations found.  
Therefore, these are proposed non-causative SNPs of any known disease at this time 
within ACAN of the horse.  
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Introduction 
 
 During the sequencing of equine ACAN, the standard sequence used in build 2.0 
as the reference sequence is from a thoroughbred, Twilight.  When using the reference 
sequence, it was noted the existence of two previously annotated SNPs in the database, 
one in exon 6 (c.1249C→ G) and the other in exon NCBI 11 (c.6592 A→ G) which is 
referred to as exon 12 in UCSC. Other SNP variations throughout the gene were 
discovered within the sample group of Miniature horses, some were synonymous and 
some caused a non-pathogenic amino acid change. These SNPs were variations to the 
reference sequence and were confirmed through repeated sequencing and trace value call 
scores above 400 using Vector NTI ContigExpress program.  There are quite possibly 
additional SNPs within this gene.  This is due to our inability to sequence entirely 
through the ~2400 bp highly conserved repeat region of exon 11.   
 
Materials and Methods 
 
Horses Used in Aggrecan SNP Study 
Two Hundred AMHA registered Miniature horses from private farms were 
phenotyped for the dwarfism study and hair, blood or postmortem tissue collected for 
DNA isolation.  Horses were selected for the SNP study were ones with a history of 
producing dwarfs or had a pedigree from known dwarf producers.  Pedigree information, 
if available, was attained through the studbook of the AMHA registry.  Stallions that had 
numbers of offspring statistically significant to consider normal for all dwarf types were 
used to compare SNPs found that were potentially non-causative.  Normal horses 
genotyped with one copy of a dwarf mutation were also used to compare SNPs.  
Homozygous dwarfs for types D1 and D2 were used as well for comparison of SNPs 
found, as well as specific novel combination dwarf samples with D3/D4, D1/D3, D1/D4, 
D2/D3 and D2/D4 genotypes. 
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DNA Sequencing 
The candidate gene, ACAN, was the gene utilized in this study.  During 
sequencing studies to determine whether mutations in this gene might cause dwarfism 
among these horses, numerous possibly non-causative SNPs were located.  Exons for 
ACAN were amplified by PCR (see Appendix for primers used for exons in 
supplementary Table 2.S3).  PCR template for sequencing was amplified in 20 µl PCR 
reactions using 1X PCR buffer with 2.0 mM MgCl₂, 200 µM of each dNTP, 1 µl 
genomic DNA from hair, blood or tissue extractions, 0.2 µl FastStart Taq DNA 
polymerase (Perkin Elmer) and 50 nM of each primer.  Each exon template PCR product 
was quantified on a 2% agarose gel run in 1X TBE solution and then amplified using the 
BigDye Terminator v1.1 cycle sequencing kit according to manufacturer’s instructions 
(Applied Biosystems, Foster City, CA).  Resulting sequence product was cleaned using 
Centri-Sep columns (Princeton Separations Inc., Adelphia, NJ), and read on an ABI 310 
genetic analyzer(Applied Biosystems).  The sequence data for exonic regions was 
compared to the reference sequence entry for equine ACAN (XM_001917528.2) using the 
reference Equuscaballus 2.0 from NCBI whole genome shotgun sequence using sequence 
viewer 2.24.  Exon sequenceswere aligned and analysed using Vector NTI Advance 10.3 
software package using ContigExpress program (Invitrogen Corporation, Carlsbad, CA).   
 
Genotype Variants  
ACAN exons were sequenced and compared among dwarf and non-dwarf 
individuals. Initially, at least six samples were sequenced for each exon. Two dwarf 
samples, two parents of the dwarf samples and two non-dwarf producing samples.  The 
non-producing samples were stallions with at least 100 registered foals with AMHA and 
producing no known dwarfs.  Once the proposed non-causative SNPs were identified, 
other dwarf samples were sequenced that were known to be homozygous for mutations 
D1 and D2, as well as normal carriers of those mutations, and novel dwarf combination 
genotypes.  At least two carriers of each dwarf mutation were also sequenced when 
possible.  This was to confirm the SNP was non-causative as well as determine if any 
were in linkage disequilibrium with any genotype, including normal. 
Results 
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The SNPs identified were variations to the reference sequence and were 
confirmed through repeated sequencing and trace value call scores above 400 using 
Vector NTI Advance 10.3 software packageContigExpress alignment program 
(Invitrogen Corporation, Carlsbad, CA).  Each SNP was categorized according to NCBI 
gene base pair number in Microsoft Excel spreadsheets with each sample sequenced and 
corresponding genotype for that sample.  Table 3.1 lists 24 proposed SNP variants 
uncovered within ACAN that have been found to not cause a dwarf phenotype.   
 
Table 3.1. Proposed non-causative SNPs found in ACAN. Shows position in genome, 
reference WT allele, mutant allele, exon location of SNP, cDNA base number of gene, 
amino acid number in gene and alteration. 
Allele Effect Chr Position Reference aMutant aExon cDNA              Protein
ACAN-N normal 1 94,381,920 G T exon 1 c.25G>T p.V9L
ACAN-N normal 1 94,379,421 A G exon 2 c.213A>G p.P71P
ACAN-N normal 1 94,374,328 T C exon 5 c.867T>C p.A289A
ACAN-N normal 1 94,372,670 C G exon 6 c.1249C>G p.P417A
ACAN-D2 dwarfism 1 94,372,629 C T exon 6 c.1290C>T p.P430P
ACAN-N normal 1 94,372,587 A G exon 6 c.1333A>G p.I445V
ACAN-N normal 1 94,370,258 G C exon 7 c.1513G>C p.A505P
ACAN-N normal 1 94,370,248 A G exon 7 c.1523A>G p.A508P
ACAN-N normal 1 94,368,175 G C exon 9 c.1888G>C p.A630P
ACAN-N normal 1 94,363,292 G A exon 11 c.2406G>A p.T802T
ACAN-N normal 1 94,363,085 G A exon 11 c.2613G>A p.G871G
ACAN-N normal 1 94,362,996 C T exon 11 c.2702C>T p.A901A
ACAN-N normal 1 94,362,939 C A exon 11 c.2759C>A p.S920T
ACAN-N normal 1 94,360,319 C T exon 11 c.5379C>T p.S1793S
ACAN-N normal 1 94,360,074 C T exon 11 c.5624C>T p.A1875V
ACAN-N normal 1 94,359,923 C T exon 11 c.5775C>T p.Y1925Y
ACAN-N normal 1 94,359,812 G A exon 11 c.5886G>A p.S1962S
ACAN-N normal 1 94,359,062 G T exon 11 c.6264G>T p.G2088G
ACAN-N normal 1 94,359,062 C T exon 11 c.6275C>T p.A2092V
ACAN-N normal 1 94,359,106 A G exon 11 c.6592A>G p.R2198G
ACAN-N normal 1 94,359,062 G A exon 11 c.6636G>A p.S2212S
ACAN-N normal 1 94,347,621 G A exon 13 c.7102G>A p.A2368T
ACAN-N normal 1 94,345,187 G C exon 16 c.7412G>C p.C2471S
ACAN-N normal 1 94,345,096 C T exon 16 c.7503C>T p.T2501T  
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Table 3.2 through Table 3.5 list specific samples sequenced and the resulting genotype at 
SNP locations as described in the following subsections for each exon.  Not all samples 
were sequenced for all exons therefore if a space is blank in Tables 3.2 – 3.5 it signifies 
that sample not having been sequenced for that specific exon. 
 
Exon 1 Non-Causative SNP 
 In exon 1 a single SNP at c.25G→T involved a change of amino acid 9 from 
valine to leucine which showed ubiquity among all genotypes within the population.   
This occurrence is non-consequential due to this exon not being translated into a part of 
the functioning protein. 
 
Exon 2 Non-Causative SNP 
 Exon 2 a synonymous SNP occurs at c.213A→G producing no change of amino 
acid.  This SNP is located upstream of the pathogenic mutation in exon 2 at c.245 and 
shows no linkage to that deletion; however it appears to show linkage disequilibrium with 
samples without the genotype D1.  Of the 59 samples sequenced for this exon, only 8 
samples possessed at least one copy of this SNP.   No sample with a genotype of D1 
possessed this base change.  More samples of the Miniature population would need to be 
analyzed to verify if this SNP is in true linkage disequilibrium with the WT genotype.  
 
Exon 5 Non-Causative SNP 
 Exon 5 a synonymous SNP occurs at c.867T→C producing no amino acid 
change.  Of the 18 samples sequenced from the population there was no linkage to any of 
the genotypes listed previously for either base T or C. 
 
Exon 6 Non-Causative SNPs 
 In exon 6 the previously annotated SNP at c.1249C→G produces the same base 
change within the Miniature horse population.   Of the 77 samples sequenced, this SNP 
shows ubiquity among all genotypes within the sample population.The SNP in exon 6 at 
c.1290C→T is a synonymous SNP that among the 77 samples shows linkage 
disequilibrium with T segregating completely with D2 genotype and the causative 
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mutation at c.1270G→A and wildtype C at c.1290C→T segregates completely with non-
carriers of D2 genotype.  This SNP could be used with the causative mutation for 
confirmation of genotype.  The SNP in exon 6 at c.1333A→G produces an amino acid 
change of Isoleucine to Valine at position 445.  This SNP change to G shows linkage 
disequilibrium with all samples not possessing a genotype of D3.  All samples with the 
genotype D3 show linkage disequilibrium with the wildtype SNP A.   
 
Exon 7 Non-Causative SNP 
 In exon 7, at base pair location c.1513G→C, change resulting in amino acid 
alanine to proline.  Also, at base pair location c.1523A→G, change resulting in amino 
acid alanine to proline.  This amino acid change possibly may cause a conformational 
change in the inter-globular domain (IGD) which is the region for aggrecanase - 1 
cleavage activity (Sandy et al. 1992).  The IGD also contains regions for proteolytic 
cleavage sitesvulnerable to a range of proteinases.  One of which is matrix 
metalloproteinases (MMPs).  The IGD also contains sites for serine proteinases some 
examples areleukocyte elastase and plasmin.  And finally, the IGD contains sites for acid 
proteinasessuch as cathepsin B (cysteine protease) (Hardingham et al. 1995: Mort et al. 
1997; Mort et al. 1998).  The non-causative snips in exon 7 are located at residues Ala 
505 to Pro 505 and Ala 508 to Pro 508.  It is not known if these changes interfere with 
the two key cleavage sites identified inthe IGD domain which are between residues Asn 
341 and Phe 342 and betweenresidues Glu 373 and Ala 374 (Singer et al. 1995; Fosang et 
al. 1996; Lark et al. 1997). 
 
Exon 9 Non-Causative SNP 
Exon 9 contains a single SNP at location c.1888G→C causing an amino acid 
change p.A630P alanine to proline.  The introduction of Pro 630 may produce a 
conformational change in the tertiary structure formation of ACAN of the G2 domain in 
this region due to the change in amino acid from residue Ala 630. 
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Exon 11 Non-Causative SNPs 
 Exon 11 (NCBI) involves a rather large highly conserved repeat (~2400 bp) that 
was not completely sequenced.   The first part of the exon prior to the repeat region, there 
were found three synonymous SNPs at c.2406G→A from 19 samples sequenced, 
c.2613G→A from 22 samples sequenced, c.2702C→T from 24 samples sequenced.  The 
next SNP, at location c.2759C→A,results in amino acid change p.S920T (serine to 
threonine).  This SNP does not show linkage disequilibrium with any genotype.  SNP 
c.2759 is located in the beginning of the repeat region of exon 11.  The repeat region 
encodes for the keratan sulfate (KS) chains of the ACAN protein and has shown 
variability in sequence length in humans (Doege et al. 1997).  Towards the latter part of 
the repeat region, a SNP at location c.5379 C→T is synonymous.  At location c.5624 
C→T, a SNP produces an amino acid change p. A1875V (alanine to valine).  This change 
shows no linkage to any genotype of the 20 samples sequenced.  SNPs at location 
c.5775C→T, 31 samples genotyped; c.5886G→A, 23 samples genotyped; c.6264G→T, 
25 samples genotyped; are all synonymous SNPs showed no linkage to a specific 
genotype.  For SNP c.6275C→T, it produces and alanine to valine amino acid change.  
Linkage disequilibrium does not appear to exist with the 28 samples sequenced.  The 
SNP at location c.6592 A→G shows no linkage disequilibrium within the 21 samples 
sequenced.  This SNP of (p.R→G) arginine to glycine amino acid change has been 
previously noted on the UCSC genome browser as a known SNP.  The SNP at location 
c.6636G→A is synonymous and more samples need to be sequenced to determine if this 
SNP is in linkage disequilibrium with a dwarf genotype/phenotype.   
 
Exon 13 Non-Causative SNP 
 Exon 13 shows a SNP located at c.7102G→A results in an amino acid change of 
p.A2368T.  Of the 16 samples, there was no linkage disequilibrium with any genotype.   
 
Exon 16 Non-Causative SNPs 
 Exon 16 shows two SNPs at location c.7412G→C producing an amino acid 
change of p.C2471S and c.7503C→T that is synonymous.   
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Table 3.2. Proposed non-causative SNPs found in ACAN for exons 1-6.  First column 
genotype of sample; N=normal, D1=dwarf type D1, D2= dwarf type D2, D3=dwarf type 
D3, D4=dwarf type D4: Second column = sample accession #: Columns of exon SNP 
genotype shows - position in genome, cDNA base number of gene, amino acid number in 
gene and alteration, sample genotype at exon location of SNP. Blank spaces indicate no 
sequence or genotype known for sample. 
ACAN exon 1 exon 2 exon 5 exon 6 exon 6 exon 6
Allele sample 94,381,920 94,379,421 94,374,328 94,372,670 94,372,629 94,372,587
c.25G>T  c.213A>G c.867T>C c.1249C>G c.1290C>T c.1333A>G 
 p.V9L p.P71P  p.A289A p.P417A  p.P430P p.I445V
2698 G/G A/A T/T G/G C/C G/G
D2/D2 2705 G/G G/G C/C C/C T/T A/A
D2/D2 2700 G/G G/G C/C C/C T/T A/A
D2/D2 2970 G/G G/G
N/D2 2971 G/G G/G
N/D1 2756 G/G G/G C/C C/C C/C G/G
N/N 2758 G/G G/G C/C G/G C/C G/G
D4/D 2676 G/T G/G C/T
N/D4 2675 G/T G/G
N/D 2677 G/T G/G
N/D2 2972 G/T G/G
N/D1 2757 G/T G/G C/C C/C G/G
N/D1 2516 G/T G/G C/T C/G C/C G/G
N/N 2726 G/T G/G T/T G/G C/C G/G
N/D1 2737 G/T G/G C/G C/C G/G
D1/D 2683 T/T G/G C/G C/C G/G
N/D 2736 T/T G/G C/G C/C G/G
D1/D 2703 T/T C/G C/C G/G
N/N 2727 T/T G/G C/T C/G C/C G/G
N/D2 2723 G/G C/G C/T A/G
N/D2 2847 G/G
D2/D 2674 G/G C/G C/T A/G
D2/D 2673 G/G C/G C/T A/G
N/D2 2724 G/G C/G C/T A/G
D2/D2 2748 G/G
D2/D 2746 G/G C/G C/T A/G  
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Table 3.2(continued). Proposed non-causative SNPs found in ACAN for exons 1-6.  First 
column genotype of sample; N=normal, D1=dwarf type D1, D2= dwarf type D2, 
D3=dwarf type D3, D4=dwarf type D4: Second column = sample accession #: Columns 
of exon SNP genotype shows - position in genome, cDNA base number of gene, amino 
acid number in gene and alteration, sample genotype at exon location of SNP. Blank 
spaces indicate no sequence or genotype known for sample. 
ACAN exon 1 exon 2 exon 5 exon 6 exon 6 exon 6
Allele sample 94,381,920 94,379,421 94,374,328 94,372,670 94,372,629 94,372,587
c.25G>T  c.213A>G c.867T>C c.1249C>G c.1290C>T c.1333A>G 
 p.V9L p.P71P  p.A289A p.P417A  p.P430P p.I445V
D2/D2 2789 G/G C/C T/T A/A
D4/D 2745 G/G C/C C/C C/C G/G
D1/D1 2738 G/G
D2/D 2749 G/G C/G C/T A/G
D2/D4 2744 G/G
N/D2 2718 G/G
N/D2 2714 G/G
D2/D 2701 G/G C/G C/T A/G
D1/D 2747 G/G C/C C/T A/G
D1/D2 2849 G/G C/C C/T A/G
D1/D 2683 G/G
D1/D2 2704 G/G C/C C/T A/G
N/D1 2513 G/G C/C C/C G/G
N/D1 2515 G/G
D2/D2 2715 G/G
N/D2 2716 G/G
D1/D2 2678 G/G C/C C/T A/G
D1/D2 2668 G/G
N/D2 2718 G/G
D1/D4 2896 G/G C/C C/C G/G
D1/D2 2719 G/G
D2/D2 2706 G/G C/C T/T A/A
N/D2 2865 G/G
D1/D2 2711 G/G
N/D2 2792 G/G
N/D1 2866 G/G
D2/D2 2709 G/G C/C
N/N 2823 G/A  
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Table 3.2(continued). Proposed non-causative SNPs found in ACAN for exons 1-6.  First 
column genotype of sample; N=normal, D1=dwarf type D1, D2= dwarf type D2, 
D3=dwarf type D3, D4=dwarf type D4: Second column = sample accession #: Columns 
of exon SNP genotype shows - position in genome, cDNA base number of gene, amino 
acid number in gene and alteration, sample genotype at exon location of SNP. Blank 
spaces indicate no sequence or genotype known for sample. 
ACAN exon 1 exon 2 exon 5 exon 6 exon 6 exon 6
Allele sample 94,381,920 94,379,421 94,374,328 94,372,670 94,372,629 94,372,587
c.25G>T  c.213A>G c.867T>C c.1249C>G c.1290C>T c.1333A>G 
 p.V9L p.P71P  p.A289A p.P417A  p.P430P p.I445V
D2/D 2906 G/A
D3/D4 2741 G/A C/T
N/D3 2742 A/A T/T G/G C/C G/G
D2/D4 2694 C/C C/T A/G
D2/D4 2696 C/C C/T A/G
D2/D3 2702 C/C C/T A/G
D2/D3 2710 C/C C/T A/G
D1/D2 2719 C/C C/T A/G
D2/D4 2751 C/C C/T A/G
N/D2 2764 C/C C/T A/G
D2/D2 2752 C/C T/T A/A
N/D1 2721 C/C C/C
N/D1 2514 C/C C/C G/G
N/D2 2669 C/G C/T A/G
D2/D 2695 C/G C/T A/G
D2/D2 2707 C/G C/T A/G
D2/D2 2708 C/G T/T A/A
N/D2 2750 C/G C/T A/G
D2/D 2911 C/G C/T A/G
N/D2 2860 C/G C/T A/G
N/D1 2880 C/G C/C G/G
N/D2 2722 C/G C/T A/G
N/D2 2518 C/G C/T A/G
N/D1 2512 C/G C/C G/G
D2/D2 2699 C/C T/T A/A
N/D2 2524 C/C C/T A/G
N/D1 2514 C/C C/C G/G
N/D4 2672
D2/D 2697   
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Table 3.3. Proposed non-causative SNPs found in ACAN for exons 7-11.  First column 
genotype of sample; N=normal, D1=dwarf type D1, D2= dwarf type D2, D3=dwarf type 
D3, D4=dwarf type D4: Second column = sample accession #: Columns of exon SNP 
genotype shows - position in genome, cDNA base number of gene, amino acid number in 
gene and alteration, sample genotype at exon location of SNP. Blank spaces indicate no 
sequence or genotype known for sample. 
ACAN exon 7 exon 7 exon 9 exon 11 exon 11 exon 11
Alleles sample 94,370,258 94,370,248 94,368,175 94,363,292 94,363,085 94,362,996
c.1513G>C c.1523A>G c.1888G>C c.2406G>A c.2613G>A c.2702C>T
p.A505P p.A508P p.A630P p.T802T p.G871G p.A901A
2698 G/G G/G G/C
D2/D2 2705 G/G G/G G/G G/G T/T
D2/D2 2700 G/G G/G
D2/D2 2970
N/D2 2971
N/D1 2756 G/G G/G G/G G/A G/G T/T
N/N 2758 G/G A/G G/G
D4/D 2676 G/C A/G G/C G/A G/A C/T
N/D4 2675
N/D 2677
N/D2 2972
N/D1 2757 G/G A/G G/G G/A G/G T/T
N/D1 2516 G/G G/G G/G G/A G/A C/T
N/N 2726 G/G G/G G/G
N/D1 2737
D1/D 2683
N/D 2736
D1/D 2703 G/A G/A C/T
N/N 2727 G/G G/G
N/D2 2723
N/D2 2847
D2/D 2674
D2/D 2673
N/D2 2724 G/G G/A C/T
D2/D2 2748
D2/D 2746  
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Table 3.3(continued). Proposed non-causative SNPs found in ACAN for exons 7-11.  
First column genotype of sample; N=normal, D1=dwarf type D1, D2= dwarf type D2, 
D3=dwarf type D3, D4=dwarf type D4: Second column = sample accession #: Columns 
of exon SNP genotype shows - position in genome, cDNA base number of gene, amino 
acid number in gene and alteration, sample genotype at exon location of SNP. Blank 
spaces indicate no sequence or genotype known for sample. 
ACAN exon 7 exon 7 exon 9 exon 11 exon 11 exon 11
Alleles sample 94,370,258 94,370,248 94,368,175 94,363,292 94,363,085 94,362,996
c.1513G>C c.1523A>G c.1888G>C c.2406G>A c.2613G>A c.2702C>T
p.A505P p.A508P p.A630P p.T802T p.G871G p.A901A
D2/D2 2789 G/G G/G G/G G/G T/T
D4/D 2745 G/G A/G G/C G/A G/G C/T
D1/D1 2738
D2/D 2749
D2/D4 2744
N/D2 2718
N/D2 2714
D2/D 2701 G/G A/G G/C G/G G/A C/T
D1/D 2747
D1/D2 2849
D1/D 2683
D1/D2 2704
N/D1 2513
N/D1 2515
D2/D2 2715
N/D2 2716
D1/D2 2678
D1/D2 2668
N/D2 2718
D1/D4 2896
D1/D2 2719
D2/D2 2706 G/G A/G
N/D2 2865 G/G A/G G/C
D1/D2 2711
N/D2 2792
N/D1 2866 G/G A/G G/G
D2/D2 2709 G/G G/G G/G
N/N 2823 G/G A/G G/G  
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Table 3.3(continued). Proposed non-causative SNPs found in ACAN for exons 7-11.  
First column genotype of sample; N=normal, D1=dwarf type D1, D2= dwarf type D2, 
D3=dwarf type D3, D4=dwarf type D4: Second column = sample accession #: Columns 
of exon SNP genotype shows - position in genome, cDNA base number of gene, amino 
acid number in gene and alteration, sample genotype at exon location of SNP. Blank 
spaces indicate no sequence or genotype known for sample. 
ACAN exon 7 exon 7 exon 9 exon 11 exon 11 exon 11
Alleles sample 94,370,258 94,370,248 94,368,175 94,363,292 94,363,085 94,362,996
c.1513G>C c.1523A>G c.1888G>C c.2406G>A c.2613G>A c.2702C>T
p.A505P p.A508P p.A630P p.T802T p.G871G p.A901A
D2/D 2906
D3/D4 2741 G/G G/G G/C G/G G/A C/T
N/D3 2742 G/C G/G G/C G/A G/G C/T
D2/D4 2694
D2/D4 2696
D2/D3 2702
D2/D3 2710
D1/D2 2719
D2/D4 2751
N/D2 2764
D2/D2 2752
N/D1 2721
N/D1 2514
N/D2 2669
D2/D 2695 G/G G/A C/T
D2/D2 2707 G/G G/A C/T
D2/D2 2708
N/D2 2750
2911
N/D2 2860
N/D1 2880
N/D2 2722
N/D2 2518
N/D1 2512
D2/D2 2699
N/D2 2524
N/D1 2514
N/D4 2672
D2/D 2697  
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Table 3.4. Proposed non-causative SNPs found in ACAN for exon 11.  First column 
genotype of sample; N=normal, D1=dwarf type D1, D2= dwarf type D2, D3=dwarf type 
D3, D4=dwarf type D4: Second column = sample accession #: Columns of exon SNP 
genotype shows - position in genome, cDNA base number of gene, amino acid number in 
gene and alteration, sample genotype at exon location of SNP. Blank spaces indicate no 
sequence or genotype known for sample. 
ACAN exon 11 exon 11 exon 11 exon 11 exon 11 exon 11
Alleles sample 94,362,939 94,360,319 94,360,074 94,359,923 94,359,812 94,359,062
c.2759C>A c.5379C>T c.5624C>T c.5775C>T c.5886G>A c.6264G>T
p.S920T p.S1793S p.A1875V p.Y1925Y p.S1962S p.G2088G
2698 C/C C/C C/C G/G G/G
D2/D2 2705 C/A T/T
D2/D2 2700
D2/D2 2970
N/D2 2971
N/D1 2756 A/A C/T C/T C/T G/G G/G
N/N 2758
D4/D 2676 C/T C/C G/G G/G
N/D4 2675 T/T C/T G/G G/G
N/D 2677
N/D2 2972
N/D1 2757 A/A C/T C/T C/T G/G G/G
N/D1 2516 A/A C/T C/T C/T
N/N 2726
N/D1 2737 C/T G/G G/G
D1/D 2683
N/D 2736 G/G G/G
D1/D 2703 C/T C/T C/T G/G
N/N 2727 C/T G/G
N/D2 2723
N/D2 2847
D2/D 2674 C/C G/A T/T
D2/D 2673 C/C C/C G/A T/T
N/D2 2724 A/A
D2/D2 2748 C/T
D2/D 2746 C/T  
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Table 3.4(continued). Proposed non-causative SNPs found in ACAN for exon 11.  First 
column genotype of sample; N=normal, D1=dwarf type D1, D2= dwarf type D2, 
D3=dwarf type D3, D4=dwarf type D4: Second column = sample accession #: Columns 
of exon SNP genotype shows - position in genome, cDNA base number of gene, amino 
acid number in gene and alteration, sample genotype at exon location of SNP. Blank 
spaces indicate no sequence or genotype known for sample. 
ACAN exon 11 exon 11 exon 11 exon 11 exon 11 exon 11
Alleles sample 94,362,939 94,360,319 94,360,074 94,359,923 94,359,812 94,359,062
c.2759C>A c.5379C>T c.5624C>T c.5775C>T c.5886G>A c.6264G>T
p.S920T p.S1793S p.A1875V p.Y1925Y p.S1962S p.G2088G
D2/D2 2789 C/C C/T A/A T/T
D4/D 2745 C/A C/T C/T C/T A/A T/T
D1/D1 2738
D2/D 2749 C/T
D2/D4 2744
N/D2 2718
N/D2 2714
D2/D 2701 C/C C/C C/C C/C G/A G/T
D1/D 2747 C/T G/T
D1/D2 2849
D1/D 2683
D1/D2 2704
N/D1 2513
N/D1 2515
D2/D2 2715
N/D2 2716
D1/D2 2678
D1/D2 2668
N/D2 2718
D1/D4 2896
D1/D2 2719
D2/D2 2706
N/D2 2865
D1/D2 2711
N/D2 2792
N/D1 2866
D2/D2 2709
N/N 2823  
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Table 3.4(continued). Proposed non-causative SNPs found in ACAN for exon 11.  First 
column genotype of sample; N=normal, D1=dwarf type D1, D2= dwarf type D2, 
D3=dwarf type D3, D4=dwarf type D4: Second column = sample accession #: Columns 
of exon SNP genotype shows - position in genome, cDNA base number of gene, amino 
acid number in gene and alteration, sample genotype at exon location of SNP. Blank 
spaces indicate no sequence or genotype known for sample. 
ACAN exon 11 exon 11 exon 11 exon 11 exon 11 exon 11
Alleles sample 94,362,939 94,360,319 94,360,074 94,359,923 94,359,812 94,359,062
c.2759C>A c.5379C>T c.5624C>T c.5775C>T c.5886G>A c.6264G>T
p.S920T p.S1793S p.A1875V p.Y1925Y p.S1962S p.G2088G
D2/D 2906 C/C G/A T/T
D3/D4 2741 C/C C/T C/T
N/D3 2742 C/A C/T C/T
D2/D4 2694 C/C G/A T/T
D2/D4 2696
D2/D3 2702
D2/D3 2710
D1/D2 2719
D2/D4 2751 C/T
N/D2 2764
D2/D2 2752
N/D1 2721
N/D1 2514
N/D2 2669
D2/D 2695 C/C C/C C/C C/C
D2/D2 2707 C/C C/C C/C C/C G/A G/T
D2/D2 2708
N/D2 2750 C/T
2911
N/D2 2860
N/D1 2880
N/D2 2722
N/D2 2518
N/D1 2512
D2/D2 2699
N/D2 2524
N/D1 2514
N/D4 2670 C/C
D2/D 2697 N/A N/A N/A N/A N/A G/T  
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Table 3.5. Proposed non-causative SNPs found in ACAN for exons 11-16.  First column 
genotype of sample; N=normal, D1=dwarf type D1, D2= dwarf type D2, D3=dwarf type 
D3, D4=dwarf type D4: Second column = sample accession #: Columns of exon SNP 
genotype shows - position in genome, cDNA base number of gene, amino acid number in 
gene and alteration, sample genotype at exon location of SNP. Blank spaces indicate no 
sequence or genotype known for sample. 
ACAN exon 11 exon 11 exon 11 exon 13 exon 16 exon 16
Alleles sample 94,359,062 94,359,106 94,359,062 94,347,621 94,345,187 94,345,096
c.6275C>T c.6592A>G c.6636G>A c.7102G>A c.7412G>C c.7503C>T
p.A2092V p.R2198G p.S2212S p.A2368T p.C2471S p.T2501T
2698 C/C G/G A/A A/A
D2/D2 2705 T/T G/G G/G
D2/D2 2700 G/G C/C C/C
D2/D2 2970
N/D2 2971
N/D1 2756 C/C G/G
N/N 2758 G/G
D4/D 2676 C/C G/G G/A G/G G/G C/T
N/D4 2675 C/C G/G G/G
N/D 2677 G/G G/A
N/D2 2972
N/D1 2757 C/C G/G G/G G/G
N/D1 2516 G/G G/G C/T
N/N 2726 G/G
N/D1 2737 C/C G/G G/A
D1/D 2683
N/D 2736 C/C G/G G/A
D1/D 2703 C/C G/G G/A
N/N 2727 G/G G/G C/T
N/D2 2723
N/D2 2847
D2/D 2674 C/T G/G G/A
D2/D 2673 C/T G/G G/A
N/D2 2724
D2/D2 2748
D2/D 2746  
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Table 3.5(continued). Proposed non-causative SNPs found in ACAN for exons 11-16.  
First column genotype of sample; N=normal, D1=dwarf type D1, D2= dwarf type D2, 
D3=dwarf type D3, D4=dwarf type D4: Second column = sample accession #: Columns 
of exon SNP genotype shows - position in genome, cDNA base number of gene, amino 
acid number in gene and alteration, sample genotype at exon location of SNP. Blank 
spaces indicate no sequence or genotype known for sample. 
ACAN exon 11 exon 11 exon 11 exon 13 exon 16 exon 16
Alleles sample 94,359,062 94,359,106 94,359,062 94,347,621 94,345,187 94,345,096
c.6275C>T c.6592A>G c.6636G>A c.7102G>A c.7412G>C c.7503C>T
p.A2092V p.R2198G p.S2212S p.A2368T p.C2471S p.T2501T
D2/D2 2789 T/T G/G G/G
D4/D 2745 C/T G/G G/G G/G C/T
D1/D1 2738 G/G T/T
D2/D 2749
D2/D4 2744
N/D2 2718
N/D2 2714
D2/D 2701 C/T G/G G/A G/G
D1/D 2747 C/T G/G G/A
D1/D2 2849
D1/D 2683 G/G G/A
D1/D2 2704
N/D1 2513
N/D1 2515
D2/D2 2715
N/D2 2716
D1/D2 2678
D1/D2 2668
N/D2 2718
D1/D4 2896
D1/D2 2719
D2/D2 2706
N/D2 2865
D1/D2 2711
N/D2 2792
N/D1 2866
D2/D2 2709 G/G
N/N 2823  
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Table 3.5(continued). Proposed non-causative SNPs found in ACAN for exons 11-16.  
First column genotype of sample; N=normal, D1=dwarf type D1, D2= dwarf type D2, 
D3=dwarf type D3, D4=dwarf type D4: Second column = sample accession #: Columns 
of exon SNP genotype shows - position in genome, cDNA base number of gene, amino 
acid number in gene and alteration, sample genotype at exon location of SNP. Blank 
spaces indicate no sequence or genotype known for sample. 
ACAN exon 11 exon 11 exon 11 exon 13 exon 16 exon 16
Alleles sample 94,359,062 94,359,106 94,359,062 94,347,621 94,345,187 94,345,096
c.6275C>T c.6592A>G c.6636G>A c.7102G>A c.7412G>C c.7503C>T
p.A2092V p.R2198G p.S2212S p.A2368T p.C2471S p.T2501T
D2/D 2906 C/T G/G G/A
D3/D4 2741 A/A
N/D3 2742 G/G
D2/D4 2694 C/T G/G G/G
D2/D4 2696
D2/D3 2702
D2/D3 2710 G/G G/G
D1/D2 2719
D2/D4 2751
N/D2 2764
D2/D2 2752
N/D1 2721
N/D1 2514
N/D2 2669
D2/D 2695 G/G
D2/D2 2707 C/T G/G G/A G/G
D2/D2 2708
N/D2 2750
2911
N/D2 2860
N/D1 2880
N/D2 2722
N/D2 2518
N/D1 2512
D2/D2 2699
N/D2 2524
N/D1 2514
N/D4 2670
D2/D 2697 C/T G/G G/A \ 
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Discussion 
Since different horses were used at times when sequencing individual exons, this 
data is a composite of partial gene sequence on the individuals used in this project.  The 
SNPs annotated in this study that cause an amino acid change at the protein level have the 
potential to have other effects within the Miniature horse that we are not aware of at this 
time.  Considering Miniature horses are the smallest of the equines and GWAS studies 
have implicated ACANas a contributor to stature in organisms, the diminutive size could 
possibly be a result from a unique mutation in ACAN that does not result in a diseased 
animal.  There are possibly other dwarf types that exist in Miniature horses that were not 
seen and acquired for the dwarfism study.  If other dwarf types are found to exist, some 
of these SNPs that appear non-causative at this time should be considered for 
investigation. 
There are quite possibly additional SNPs within this gene.  This study only 
considered the sequences of Miniature horses to the reference sequence of a 
Thoroughbred, Twilight.  With the existence of numerous other breeds of equines 
throughout the world, it is likely more variability exists in the sequence of ACAN.  With 
better understanding of the exons expressed in ACAN in articular cartilage and other 
tissues, we will have a more accurate information to determine the correct exon number 
and splicing information. 
The inability to sequence entirely through the ~2400 bp highly conserved repeat 
region of exon 11 restricted our efforts to better understand the highly conserved 
sequence of the KS domain in ACAN. This region of ACAN has interesting and unique 
properties in structure and function for ACAN and more importantly the ECM and has 
great potential in all areas of research. 
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Chapter 4 
Reflections on Project Complexity, Technology, Remaining Questions 
 
Summary of Aggrecan and Dwarfism study in Miniature horses 
Thesis Goals 
The primary works of this thesis were focused towards the discovery of the genetic cause 
of a common type of dwarfism in the Miniature horse with an ultimate goal of providing a 
genetic test for the breeders of Miniature horses to assist them in identifying carriers and better 
managing those horses with the genetic defect.  More specifically, the objectives were: (1) 
collect, identify and categorize the different dwarf phenotype samples and related unaffected 
individuals that exist in the breed, (2) from the dwarf samples gathered throughout the United 
States, determine the most common type and provide documentation and physical description of 
that phenotype, (3) to utilize GWAS techniques to find the genetic cause of that type, (4) design 
a genetic test that can be employed by genetic testing labs for the breeders of Miniature horses.  
 
Project Complexity  
Utilizing the GWAS technique was crucial in this project.  With the advent of the equine 
genome being sequenced, this new technology afforded the equine genetics research community 
the ability to find a genetic cause of a disease in a breeding population that would otherwise not 
have been possible.  Family studies of dwarfism within the Miniature horse breed would have 
been difficult.  This difficulty is in large part due to the inaccuracies with pedigree information 
of the Miniature horse breed, confidentiality concerns, and sensitivity of breeders.The origins of 
these mutations will not be completely understood.  This is due to the breeding practices in the 
foundation of the breed, and the use of numerous different pony breeds and various other larger 
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horse breeds to ultimately produce the Miniature horse of today.  These mutations show evidence 
to be exclusively within the Miniature horse breed.  These dwarf types have not been 
documented to exist in any other pony or large horse breed.  Miniature horses have other dwarf 
types not involving Acan and have a type similar to dwarfism in the Friesian mentioned earlier. 
This provides strong support that these mutations are relatively new within the equine genome.  
More specifically, it is probable these mutations arose within the smaller pony breeds in the 
United States given the anecdotal history of how many of the first Miniature horse breeders were 
well-known pony breeders.  Other anecdotal evidence mentions that some of the first small 
ponies in America, referred to by the Shetland pony breeders as “midget ponies”, were later 
some of the first registered Miniature horses. 
This thesis began a project that has become more intricate and complicated than was 
originally designed.  This is due mainly to the most common phenotype of dwarfism in the 
Miniature horse being a compound heterozygote of two different recessive mutations of the same 
gene independently segregating in the population and ultimately leading to the discovery of two 
other mutations with less allelic frequency in the sample group.  This thesis began a process that 
will take much more time and effort in order to properly annotate and categorize these different 
mutations that have been discovered and determine how they affect the Miniature horse. 
 
Remaining Questions - Possible Future Projects Moving Forward  
Some possible projects that could emanate from this original work could involve various 
specialties of equine research.  The following is a list of possible projects that could be beneficial 
to the equine research community and breeders of Miniature horses. 
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Quantify exon 11 deletion in the Miniature population 
 This mutation exists in a small portion of compound heterozygote dwarf samples within 
this project.  Designing a reliable Taqman® SNP Genotyping Assay (Applied Biosystems) for 
this mutation would need to be accomplished.  Testing of dwarf samples within this study that 
are of unknown status with regards to the mutations found and /or are heterozygous for a known 
mutation would need to be performed.  Also, testing of non-dwarf individuals in the control 
population of this study group would need to be performed as well.  However, testing other 
dwarfs of unknown cause that do not exhibit the genetic mutations found in this thesis would 
need to be performed to discover status, i.e. Miniature horse dwarfs with skeletal atavism.  To 
further determine population penetrance of this mutation within the breed, a large random group 
of individuals in the population could be tested.   This large group could be utilized to determine 
the penetrance of the other mutations found in Acan that cause dwarfism as well. 
 
Pathological Examination of Articular Cartilage and ECM of 4 Mutations of Aggrecan Causing 
Dwarfism 
 This project would entail work in Equine Pathology and/or Musculoskeletal Sciences.  
Acan is an integral part of cartilage and allows the ECM to function properly.  Acan is the reason 
weight bearing cartilage can retain water enabling joints to handle the stresses experienced on a 
daily basis.   Four different independently segregating mutations within this gene cause dwarfism 
in the Miniature horse.  This project’s goal would be to determine through examination of the 
cellular structures of articular cartilage how each of these mutations affect the horse in 
homozygous form and in compound heterozygous form to produce the resulting phenotypes seen 
in the breed.  Collecting cartilage tissue and bone samples of each donated dwarf would be done 
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after DNA testing provided genotype confirmation of mutations the dwarf carried.  Physical 
records with picture documentation would be performed of phenotype with detailed gross 
anatomical descriptions of each homozygous mutation and novel combinations.  Microscopic 
examinations would be performed on specific cartilage samples of each type of dwarf to provide 
explanation of resulting cartilage and bone malformations due to the mutations. 
 
Use of Vector / Plasmid to Sequence the CS Region of Equine Aggrecan  
 A large portion of the CS region of Equine Acanwas not able to be sequenced by typical 
short run sequencing utilized in this project by the ABI 310 genetic analyzer.  Due to the high 
conservation of sequence and unique repeat pattern of the CS region in exon 11 of Acan, it is not 
possible with current sequencing technology to read through this region in a single long read and 
produce consist and reliable results.  Therefore, a project utilizing unique restriction enzyme 
splice sites that sections this ~2.4 – 3.5 kb DNA sequence into sizes that could be inserted in 
plasmids / vectors and then be reliably sequenced by a short read sequencer repeatedly could be 
designed.  First would be to determine the existence of length variability within this region by 
simply designing reliable primers and PCR protocol that produced consistent bands of reliable 
size.  In humans, this region has been shown to be highly variable in the general population 
(Doege et al. 1997).  This would be a key to know in the horse to determine possible splice site 
variability thus possible fragment size variability with digestion and transfection ultimately 
causing sequence read overlapping inconsistencies.  If there is variability in sequence length of 
the CS region, the PCR protocol could be utilized to determine allelic variability in the size of 
this repeat region in the equine species as a whole or even a specific breed.  If Allelic variability 
exists within the equine, the samples that are determined to be homozygous for an allelic size 
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could then be utilized in the vector /plasmid transfection protocol for sequencing that allelic size.  
This region would also be an area to consider for any unknown dwarf types seen in the Miniature 
horse that do not express the four mutations described here.  
 
Final Thoughts 
Evaluating the Miniature horse’s foundation provides a general concept of the genetic 
diversity that has ultimately produced this breed.  It is necessary to understand the foundation 
and breeding practices of this breed in order to better comprehend the inherited genetic problems 
that permeate it.  The goal of the Miniature horse is to breed the smallest most correct and 
proportionate horse in miniature.  However, small size was the overriding breeding criteria used 
in the mid to later part of the 20th century, during the greatest popularity of the breed and 
population boom.  With this variation in genetics, the desire to produce the smallest Miniature 
horses and having no strict quality standards of bloodstock led to the use of severely malformed 
small Miniature horses being used in breeding programs.  A majority of these conformationally 
inferior Miniature horses showed consistent physical abnormalities typical of disproportionate 
dwarfisms as seen in other mammal species.  Disproportionate dwarfism in Miniature horses, in 
the decades past, has been a well-known unspoken problem within the breed and has known to 
exist through anecdotal evidence and record keeping of breeders.  This problem has now become 
a more openly discussed concern within the Miniature horse industry throughout the world.  
Dwarf Miniature horses, while often setting world records for small size are not considered to 
have desirable traits.  These horses possessing incorrect conformation typical of disproportionate 
dwarfism have significant health, quality of life and soundness issues.  Therefore, many 
Miniature horse registries try to avoid accepting Miniature horses affected by dwarfism for 
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breeding stock during the registration process (AMHA 2012; AMHR 2012). Unfortunately, 
Miniature horses which are not dwarfs and are small in size may also express extremely inferior 
conformational characteristics. These individuals may be confused with dwarfism and therefore 
compound the problem of identification of actual dwarfism and identification of other possible 
inferior genetic issues within the breed.  These other inferior individuals, along with dwarfs, are 
still used in some breeding programs today to produce the smallest horse possible.  These 
practices may reveal the possibility of the existence of other mutations that cause a type of 
dwarfism within Acan that was not found in this project or even a mutation of a different genetic 
cause. 
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APPENDIX 
 
Supplementary Data, Tables and Figures 
 
 
Table 2.S1. Shows the 10 most significant associations found for SNPs and the 
occurrence of dwarfism.  The only SNP that achieved statistical significance based on 
EMP2 score was BIEC2_38994 found on ECA1.  This observation was supported by 6 of 
the 10 strongest associations occurring with SNPs on ECA1.  
CHR SNP Chi-Square EMP2
1 BIEC2_38994 23.54 0.01898
1 BIEC2_40049 18.92 0.1558
1 BIEC2_38884 18.83 0.1628
1 BIEC2_38959 17.1 0.3516
1 BIEC2_38970 17.1 0.3516
8 BIEC2_1027066 16.89 0.3956
1 BIEC2_39609 15.75 0.5315
5 BIEC2_901067 14.1 0.7892
31 BIEC2_841695 13.63 0.8631
22 BIEC2_577120 13.28 0.8911  
 
 
 
Table 2.S2 
Haplotypes with SNP BIEC2_38994 shows 5 Haplotypes among dwarfs. 
Genotype Dwarf Control
1/2 1 7
1/3 6 1
2/2 0 8
2/3 4 5
2/4 0 1
2/5 1 0
3/3 5 0
3/5 2 0
4/5 0 1
19 23  
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Table 2.S3. Primers used for ACAN sequencing exons 1-17 Lower case sequences 
indicate intron.  Upper case indicate exon.Exon numbering is according to UCSC 
Genome browser prediction onEcab build 2.0.  
Exon # Forward Primer Sequence Reverse Primer Sequence
Exon 1 gtgacctttgccctcactgt gcacccagaatccagtcttc
Exon 2 tgggtggtcctctctagcac tttccacaggtgaagcaaca
Exon 3 gtgcctgacctgctctatcg agctcagtgctggtcaacg
Exon 4 cctgagtgtcacatcccactt gagtggtagtggggtgaagg
Exon 5 gcctgctttgtccttcacag aaaacagccccctattccac
Exon 6 gggctgagccgctaaagtt aggccaagttccttccactt
Exon 7 gtctctccttctcgccctct aagcctgacccttgagactg
Exon 8 agaacaggccctcattctgc aggtaatgccctctcctcgt
Exon 9 gtgccacctgcctctgtc cagaagtgggttctggagga
Exon 10 aggaggaaccttcaccacct cgcccaagccatacgaac
Exon 11a ggagcagtttctaatcccaca ACTGAGGTCCTCTGCTCCAG
Exon 11b TATCTCTGCAGTGGGCTCAG AGGCAGTGGGCTCTAGATGA
Exon 11c GAGTGGAGGACCTTGGTGAA gaggcagtgggctctaaatg
Exon 12a tgcctccggagtagaggac TGACGACTTCCACCAATGTC
Exon 12b GGCAAGCTCCTGAAGCAAGT TCCAGATGTTGTCCCACTGA
Exon 12c GTGGACTGTCCTCTGGACAAC CCCTTCTCCTGCTTCTTGG
Exon 12d TCCTCTGGAGCTGAGACTGG ATCAGGGGACCCAGAAGC
Exon 12e CCCAGCTTGTTGAGTCCAGT ctgaactacccaaaccccttt
Exon 13 cttcaagcccctgacctgt ctgctgacttctggcaagtg
Exon 14 cccaaacccacatcttctct atgccgtccgaatgtatctc
Exon 15 ctgccctctgctcacctct ggagccgaagtcttgattct
Exon 16 cacaggagccctttctgaag cagggaggaggaggtgct
Exon 17 ccgagggctcactaggattt gacgaagtgtcggtgatctg  
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Table 2.S4. Testing results of samples using Taqman® RT-PCR for exons 2 and 6.  As 
well as PCR results of exon 15 run on 2% agarose gel. Taqman® exon 6; CC = Normal 
genotype, CT= Carrier genotype D2:  Taqman® Exon 2: AA = Normal genotype, A- = 
Carrier genotype D1: Exon 15; CC = Normal genotype, C- = Carrier genotype. 
Acc. # Breed Taqman exon 6 Taqman exon 2 Exon 15 Del
13307 AMHR CT AA CC
13308 AMHR CC AA CC
13309 AMHR CC AA CC
13310 AMHR CC AA CC
13311 AMHR CC AA CC
13312 AMHR CC AA CC
13313 AMHR CC AA CC
13314 AMHR CC AA CC
13315 AMHR CC AA CC
13316 AMHR CC AA CC
13317 AMHR CC AA CC
13318 AMHR CC AA CC
13319 AMHR CC AA CC
13320 AMHR CC AA CC
13321 AMHR CC AA CC
13322 AMHR CC AA CC
13323 AMHR CC AA CC
13324 AMHR CC AA CC
13325 AMHR CC AA CC
13326 AMHR CC AA CC
13327 AMHR CC AA CC
13328 AMHR CC AA CC
13329 AMHR CC AA CC
13330 AMHR CC AA CC
13462 AMHR CC AA CC
13463 AMHR CC AA CC
13464 AMHR CC AA CC
13465 AMHR CC AA CC
13466 AMHR CC AA CC
13467 AMHR CC AA CC
13468 AMHR CC AA CC
13469 AMHR CC AA CC
13470 AMHR CC AA CC
13471 AMHR CC AA CC
13472 AMHR CC AA CC
13473 AMHR CC AA CC
13474 AMHR CC AA CC
13475 AMHR CT AA CC
13476 AMHR CC AA CC  
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Table 2.S4(continued). Testing results of samples using Taqman® RT-PCR for exons 2 
and 6.  As well as PCR results of exon 15 run on 2% agarose gel. Taqman® exon 6; CC = 
Normal genotype, CT= Carrier genotype D2:  Taqman® Exon 2: AA = Normal genotype, 
A- = Carrier genotype D1: Exon 15; CC = Normal genotype, C- = Carrier gentoype 
Acc. # Breed Taqman exon 6 Taqman exon 2 Exon 15 Del
H102526 AMHR CC AA CC
H102527 AMHR CC AA CC
H102528 AMHR CC AA CC
2936 AMHR CC AA CC
2798 Hackney CC AA CC
2813 Caspian CC AA CC
1835 ARA CC AA CC
1836 ARA CC AA CC
1827 ARA CC AA CC
1828 ARA CC AA CC
Q1-17 SAB CC AA CC
R1-20 SAB CC AA CC
R1-12 SAB CC AA CC
R1-14 SAB CC AA CC
C-180 TW CC AA CC
C-110 TW CC AA CC
C-230 TW CC AA CC
C-120 TW CC AA CC  
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Table 2.S4(continued). Testing results of samples using Taqman® RT-PCR for exons 2 
and 6.  As well as PCR results of exon 15 run on 2% agarose gel. Taqman® exon 6; CC = 
Normal genotype, CT= Carrier genotype D2:  Taqman® Exon 2: AA = Normal genotype, 
A- = Carrier genotype D1: Exon 15; CC = Normal genotype, C- = Carrier gentoype 
Acc. # Breed Taqman exon 6 Taqman exon 2 Exon 15 Del
Standard Twilight TB CC AA CC
2433 TB CC AA CC
1197 TB CC AA CC
2449 TB CC AA CC
307 TB CC AA CC
1178 TB CC AA CC
431 TB CC AA CC
421 TB CC AA CC
1179 TB CC AA CC
463 TB CC AA CC
1273 TB CC AA CC
1261 TB CC AA CC
315 TB CC AA CC
415 TB CC AA CC
429 TB CC AA CC
1195 TB CC AA CC
457 TB CC AA CC
1232 TB CC AA CC
2269 TB CC AA CC
1345 TB CC AA CC
467 TB CC AA CC
471 TB CC AA CC
472 TB CC AA CC
475 TB CC AA CC
603 TB CC AA CC
605 TB CC AA CC
622 TB CC AA CC
1242 TB CC AA CC  
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Table 2.S4(continued). Testing results of samples using Taqman® RT-PCR for exons 2 
and 6.  As well as PCR results of exon 15 run on 2% agarose gel. Taqman® exon 6; CC = 
Normal genotype, CT= Carrier genotype D2:  Taqman® Exon 2: AA = Normal genotype, 
A- = Carrier genotype D1: Exon 15; CC = Normal genotype, C- = Carrier gentoype 
Acc. # Breed Taqman exon 6 Taqman exon 2 Exon 15 Del
923 ST CC AA CC
924 ST CC AA CC
925 ST CC AA CC
926 ST CC AA CC
927 ST CC AA CC
928 ST CC AA CC
929 ST CC AA CC
930 ST CC AA CC
931 ST CC AA CC
932 ST CC AA CC
933 ST CC AA CC
934 ST CC AA CC
935 ST CC AA CC
936 ST CC AA CC
937 ST CC AA CC
938 ST CC AA CC
939 ST CC AA CC
940 ST CC AA CC
942 ST CC AA CC
943 ST CC AA CC
944 ST CC AA CC
945 ST CC AA CC  
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